HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF

Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.

Description: HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF FIELD OF THE INVENTION This application relates to hepatocyte growth factor receptor antagonists. The application also relates to the use of the antagonists in therapy or diagnosis of particular pathological conditions in mammals, including cancer. BACKGROUND OF THE INVENTION Hepatocyte growth factor ("HGF") functions as a growth factor for particular tissues and cell types. HGF was identified initially as a mitogen for hepatocytes [Michalopoulos et al., Cancer Res..44:4414- 4419 (1984); Russel et al., J. Cell. PhvsioL 112:183-192 (1984); Nakamura et al., Biochem. Biophvs. Res. Comm..122:1450-1459 (1984)]. Nakamura et al., supra, reported die purification of HGF from the serum of partially hepatectomized rats. Subsequently, HGF was purified from rat platelets, and its subunit structure was determined [Nakamura et al., Proc. Natl. Acad. Sci. USA. £2:6489-6493 (1986); Nakamura et al., FEBS Letters. 224:311-316 (1987)]. The purification of human HGF ("huHGF") from human plasma was first described by Gohda et al., J. Clin. Invest.. $1414-419 ( 1988). Both rat HGF and huHGF have been molecularly cloned, including the cloning and sequencing of a naturally occurring variant lacking 5 amino acids designated "delta5 HGF" [Miyazawa et al., Biochem. Biophys. Res. Comm.. 163:967-973 (1989); Nakamura et al., Nature. 342:440-443 (1989); Seki et al, Biochem. Biophvs. Res. Commun..122:321-327 (1990); Tashiro et al., Proc. Natl. Acad. Sci. USA. ££3200-3204 (1990); Okajima et al., Eur. J. Biochem..121:375-381 (1990)]. The mature form of huHGF, corresponding to the major form purified from human serum, is a disulfide linked heterodimer derived by proteolytic cleavage of the human pro-hormone between amino acids R494 and V495. This cleavage process generates a molecule composed of an α-subunit of 440 amino acids (M r 69 kDa) and a β-subunit of 234 amino acids (M j .34 kDa). The nucleotide sequence of the huHGF cDNA reveals that both the α- and the β -chains are contained in a single open reading frame coding for a pre-pro precursor protein. In the predicted primary structure of mature huHGF, an interchain S-S bridge is formed between Cys 487 of the α -chain and Cys 604 in the β -chain [see Nakamura et al., Nature, supra! . T e N-terminus of the α- chain is preceded by 54 amino acids, starting with a methionine group. This segment includes a characteristic hydrophobic leader (signal) sequence of 31 residues and the prosequence. The -chain starts at amino acid (aa) 55, and contains four kringle domains. The kringle 1 domain extends from about aa 128 to about aa 206, the kringle 2 domain is between about aa 211 and about aa 288, the kringle 3 domain is defined as extending from about aa 303 to about aa 383, and the kringle 4 domain extends from about aa 391 to about aa 464 of the α- chain. The definition of the various kringle domains is based on their homology with kringle-like domains of other proteins (such as prothrombin and plasminogen), therefore, the above limits are only approximate. To date, the function of these kringles has not been determined. The β-chain of huHGF shows high homology to the catalytic domain of serine proteases (38% homology to the plasminogen serine protease domain). However, two of the three residues which form the catalytic triad of serine proteases are not conserved in huHGF. Therefore, despite its serine protease-like domain, huHGF appears to have no proteolytic activity, and die precise role of the β-chain remains unknown. HGF contains four putative glycosylation sites, which are located at positions 294 and 402 of the α-chain and at positions 566 and 653 of the β-chain. Comparisons of the amino acid sequence of rat HGF with that of huHGF have revealed that the two sequences are highly conserved and have the same characteristic structural features. The length of the four kringle domains in rat HGF is exactly the same as in huHGF. Furthermore, the cysteine residues are located in exactly the same positions, an indication of similar three-dimensional structures [Okajima et al., supra: Tashiro et al., supra] . In a portion of cDNA isolated from human leukocytes, in-frame deletion of 15 base pairs was observed. Transient expression of the cDNA sequence in COS-1 cells revealed that the encoded HGF molecule (delta5 HGF) lacking 5 amino acids in the kringle 1 domain was fully functional [Seki et al., supra] . A naturally occurring huHGF variant has been identified which corresponds to an alternative spliced form of the huHGF transcript containing the coding sequences for the N-terminal finger and first two kringle domains of mature huHGF [Chan et al., Science. 254:1382-1385 (1991); Miyazawa et al., Eur. J. Biochem..197:15-22 (1991)]. This variant, designated HGF/NK2, has been proposed by some investigators to be a competitive antagonist of mature huHGF. Hartmann et al. have reported, however, that HGF/NK2 may retain the ability to cause MDCK cells to scatter [Hartmann et al., Proc. Natl. Acad. Sci.. 89:11574-1 1578 (1992)]. Another HGF variant, designated HGF/N l, has also been reported to act as a competitive antagonist of HGF [Lokker et al., J. Biol. Chem.. 26J5: 17145- 17150 (1993); Lokker et al., EMBO J.. JJ.:2503- 2510 (1992)]. That HGF NKl molecule, containing the N-terminal haiφin and the first kringle domain, was found to block binding of HGF to the HGF receptor on A549 human lung carcinoma cells. It was also found, however, that certain concentrations of the HGF/NKl induced a detectable increase in receptor tyrosine phosphorylation in the A549 cells, suggesting some agonistic activity. Accordingly, it is believed that the agonist or antagonist action of HGF/NKl may be dependent upon cell type. HGF and HGF variants are described further in U.S. Patent Nos. 5,227, 158, 5,316,921 , and 5,328,837. A high affinity receptor for HGF has been identified as the product of the c-Met proto- oncogene [Bottaro et al., Science. 25 .:802-804 (1991); Naldini et al., Oncogene. 6:501-504 (1991); WO 92/13097 published August 6, 1992; WO 93/15754 published August 19, 1993]. This receptor is usually referred to as "c-Met" or "pl90 MET " and typically comprises, in its native form, a 190-kDa heterodimeric (a disulfide-iinked 50-kDa α-chain and a 145-kDa β-chain) membrane-spanning tyrosine kinase protein [Park et al., Proc. Natl. Acad. Sci. USA. £4:6379-6383 (1987)]. Several truncated forms of the c-Met receptor have also been described [WO 92/20792; Prat et al., Mol. Cell. Biol..11:5954-5962 (1991)]. The binding activity of HGF to c-Met is believed to be conveyed by a functional domain located in the N-terminal portion of the HGF molecule, including the first two kringles [Matsumoto et al., Biochem. Biophvs. Res. Commun.. 181 :691-699 (1991); Hartmann et al., Proc. Natl. Acad. Sci.. ≤9:11574- 11578 (1992); Lokker et al., EMBO J..11:2503-2510 (1992); Lokker and Godowski, J. Biol. Chem..2≤8: 17145- 17150 (1991)]. The c-Met protein becomes phosphorylated on tyrosine residues of the 145-kDa β-subunit upon HGF binding. Certain antibodies to this HGF receptor have been reported in the literature. Several such antibodies are described below. Prat et al., Mol. Cell. Biol.. supra, describe several monoclonal antibodies specific for the extracellular domain of the β-chain encoded by the c-Met gene [see also, WO 92/20792]. The monoclonal antibodies were selected following immunization of Balb/c mice with whole living GTL- 16 cells (human gastric carcinoma cell line) overexpressing the Met protein. The spleen cells obtained from the immunized mice were fused with Ag8.653 myeloma cells, and hybrid supernatants were screened for binding to GTL- 16 cells. Four monoclonal antibodies, referred to as DL-21, DN-30, DN-31 and DO-24, were selected. Prat et al., Int. J. Cancer.42:323-328 (1991) describe using anti-c-Met monoclonal antibody DO-24 for detecting distribution of the c-Met protein in human normal and neoplastic tissues [see, also, Yamada et al., Brain Research. £3.7:308-312 (1994)]. The murine monoclonal antibody DO-24 was reported to be an IgG2a isotype antibody. Crepaldi et al., J. Cell Biol.. 125: 313-320 (1994) report using monoclonal antibodies DO-24 and DN-30 [described in Prat et al., Mol. Cell. Biol.. supra! and monoclonal antibody DQ-13 to identify subcellular distribution of HGF receptors in epithelial tissues and in MDCK cell monolayers. According to Crepaldi et al., monoclonal antibody DQ-13 was raised against a peptide corresponding to nineteen COOH- ι ■* t 9 1 QA terminal amino acids (from Ser 1 J " • to Ser 1 Jyυ ) of the human c-Met sequence. A monoclonal antibody specific for the cytoplasmic domain of human c-Met has also been described [Bottaro et al., supral. Several of the monoclonal antibodies referenced above are commercially available from Upstate Biotechnology Incoφorated, Lake Placid, New York. Monoclonal antibodies DO-24 and DL-21, specific for the extracellular epitope of c-Met, are available from Upstate Biotechnology Incoφorated. Monoclonal antibody DQ-13, specific for the intracellular epitope of c-Met, is also available from Upstate Biotechnology Incoφorated. In addition to binding c-Met, it is recognized that HGF binds to some heparin and heparan sulfate proteoglycans which are present on cell surfaces or in extracellular matrices [Rouslahti et al., Cell. £4:867-869 (1991); Lyon et al., J. Biol. Chem.. 262:1 1216-11223 (1994)]. Heparan sulfate is a glycosaminoglycan similar in composition and structure to heparin and is found on many mammalian cell surfaces. Various hypotheses have been proposed to explain the role of heparin and heparan sulfate proteoglycans ("HPSGs") in the regulation of certain growth factor activity. For example, it has been hypothesized that upon binding heparin or HSPGs, certain growth factors may have a more favorable conformation for binding to their respective high affinity receptors [Lindahl et al., Annual Rev. Biochem.. 42:385-417 (1995)]; that HSPGs may serve as docking sites for certain growth factors facilitating the presentation of ligand to its high affinity receptor [Yayon et al., Cell. £4:841-848 (1991); Moscatelli et al., Biol. Chem..262:25803-25809 (1992); Nugent et al., Biochemistry.11:8876-8883 (1992)]; and that HSPGs may promote ligand dimerization facilitating receptor activation [Ornitz et al., Mol. Cell. Biol..12:240-247 (1992); Spivak-Kroizman et al., Cell.22:1015-1024 (1994)]. It has further been postulated that certain growth factors are more stable or resistant to proteolytic activity [Damon et al., J. Cell. Phvsio 138:221 -226 ( 1989); Mueller et al., J. Cell. PhvsioL.140:439-448 (1989); Rosengart et al., Biochem. Biophvs. Res. Commun.. 152:432-440 ( 1998)] and denaturation [Copeland et al., Arch. Biochem. Biophvs..2S2:53-61 ( 1994)] when bound to heparin. Coincubation of HGF with soluble heparin and other heparin-like molecules has been reported to promote dimerization/oligomerization of HGF and to potentiate HGF mitogenic activity, [see, e.g., WO 94/09969 published March 16, 1995; Zioncheck et al., J. Biol. Chem..22Q: 16871-16878 (1995)]. Mizuno et al. describe some experiments which attempted to locate heparin-binding sites within the HGF molecule [Mizuno et al., J. Biol. Chem..262:1131-1136 (1994)]. Mizuno et al. constructed variously deleted mutant HGFs [d-Kl (deletion of first kringle domain); d-K2 (deletion of second kringle domain); d-K3 (deletion of third kringle domain); d-K4 (deletion of fourth kringle domain); d-beta (deletion of beta chain); d-H (deletion of N-terminal haiφin loop); and HK1K2 (consisting of N-terminal haiφin loop and the first and second kringle domains)] and examined their respective binding to an immobilized heparin column. The reference reports that the d-H and d-K2 mutants exhibited decreased binding to heparin affinity columns, while the native HGF and the other constructed HGF mutants tightly bound to the heparin columns. Various biological activities have been described for HGF and its c-Met receptor [see, generally, Chan et al., Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the C-Met Receptor. Goldberg and Rosen, eds., Birkhauser Verlag-Basel (1993), pp. 67-79]. It has been observed that levels of HGF increase in the plasma of patients with hepatic failure [Gohda et al., supra] and in the plasma [Lindroos et al., Hepatol.. 11:734-750 (1991)] or serum [Asami et al., J. Biochem.. 1H2:8-13 (1991)] of animals with experimentally induced liver damage. The kinetics of this response are usually rapid, and precedes the first round of DNA synthesis during liver regeneration. HGF has also been shown to be a mitogen for certain cell types, including melanocytes, renal tubular cells, keratinocytes, certain endothelial cells and cells of epithelial origin [Matsumoto et al., Biochem. Biophvs. Res. Commun..126:45-51 ( 1991 ); Igawa et al., Biochem. Biophvs. Res. Commun.. 124:831-838 (1991); Han et al., Biochem.. !0_:9768-9780 (1991); Rubin et al., Proc. Natl. Acad. Sci. USA. S§:415-419 (1991)]. Both HGF and the c-Met protooncogene have been postulated to play a role in microglial reactions to CNS injuries [DiRenzo et al., Oncogene. &219-222 (1993)]. HGF can also act as a "scatter factor", an activity that promotes the dissociation of epithelial and vascular endothelial cells in vitro [Stoker et al., Nature.122:239-242 ( 1987); Weidner et al., J. Cell Biol.. 111:2097-2108 (1990); Naldini et al., EMBO J..1&2867-2878 (1991); Giordano et al., Proc. Natl. Acad. Sci. USA.22:649-653 (1993)]. Moreover, HGF has recently been described as an epithelial moφhogen [Montesano et al., Cell. 62:901-908 (1991)]. Therefore, HGF has been postulated to be important in tumor invasion [Comoglio, Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the C-Met Receptor. Goldberg and Rosen, eds., Birkhauser Verlag-Basel (1993), pp. 131-165]. Bellusci et al., Oncogene.2:1091-1099 (1994) report that HGF can promote motility and invasive properties of NBT-II bladder carcinoma cells. c-Met RNA has been detected in several murine myeloid progenitor tumor cell lines [Iyer et al., Cell Growth and Differentiation.1:87-95 (1990)]. Further, c-Met is expressed in various human solid tumors [Prat et al., Int. J. Cancer, supra]. Overexpression of the c-Met oncogene has also been suggested to play a role in die patiiogenesis and progression of thyroid tumors derived from follicular epithelium [DiRenzo et al., Oncogene. 2:2549-2553 (1992)]. Chronic c-Met/HGF receptor activation has also been observed in certain malignancies [Cooper et al., EMBO J.. 5_:2623 (1986); Giordano et al., Nature. U2:155 (1989)]. In view of the role of HGF and/or c-Met in potentiating or promoting such diseases or pathological conditions, it would be useful to have a means of substantially reducing or inhibiting one or more of the biological effects of HGF and c-Met. SUMMARY OF THE INVENTION The invention provides HGF receptor antagonists which are capable of specifically binding to a HGF receptor. Preferred HGF receptor antagonists are capable of substantially reducing or inhibiting the mitogenic. motogenic (migration or scatter) or other biological activity of HGF or HGF receptor activation, and thus are useful in the treatment of various diseases and pathological conditions such as cancer. In one embodiment of the invention, the HGF receptor antagonist is an antibody. Preferably, this antagonist is a monoclonal antibody, and more preferably, is a Fab fragment of a monoclonal antibody. The invention also provides hybridoma cell lines which produce HGF receptor antagonist monoclonal antibodies. The invention also provides HGF receptor antagonists that comprise isolated polypeptide comprising the amino acid sequences of Figure IA (SEQ ID NO:l) and Figure IB (SEQ ID NO:2). The polypeptides consisting of the amino acid sequences of Figure 1 A (SEQ ID NO: 1 ) and Figure 1 B (SEQ ID NO:2) correspond to the light chain and heavy chain, respectively, of monoclonal antibody 5D5 Fab, described herein. The invention also provides chimeric molecules comprising HGF receptor antagonist linked or fused to another, heterologous polypeptide or polymer. An example of such a chimeric molecule comprises a HGF receptor antagonist amino acid sequence linked or fused to an albumin sequence or polyethylene glycol ("PEG") sequence. The invention further provides an isolated nucleic acid molecule encoding HGF receptor antagonist. In one aspect, the nucleic acid molecule is RNA or DNA that encodes a HGF receptor antagonist or is complementary to a nucleic acid sequence encoding such HGF receptor antagonist, and remains stably bound to it under stringent conditions. In one embodiment, the nucleic acid sequences are selected from: (a) the nucleic acid sequence of Figure IA that codes for residue 1 to residue 220 (i.e., nucleotides 1 through 660; SEQ ID NO:3), inclusive; (b) the nucleic acid sequence of Figure IB that codes for residue 1 to residue 230 (i.e., nucleotides 1 through 690; SEQ ID NO:4), inclusive; or (c) a nucleic acid sequence corresponding to the sequence of (a) or (b) within the scope of degeneracy of the genetic code. The invention also provides a replicable vector comprising the nucleic acid molecule(s) encoding die HGF receptor antagonist operably linked to control sequence(s) recognized by a host cell transfected or transformed with the vector. A host cell comprising die vector or the nucleic acid molecule(s) is also provided. A method of producing HGF receptor antagonist which comprises culturing a host cell comprising die nucleic acid molecule(s) and recovering the protein from the host cell culture is further provided. The invention also provides pharmaceutical compositions comprising one or more HGF receptor antagonists in a pharmaceutically-acceptable carrier. In one embodiment, the pharmaceutical composition may be included in an article of manufacture or kit. The invention also provides methods of employing HGF receptor antagonists, including methods of inhibiting HGF receptor activation. The invention further provides methods for treating cancer comprising administering to a mammal diagnosed as having cancer an effective amount of a HGF receptor antagonist. The HGF receptor antagonist alone may be administered to the mammal, or alternatively, may be administered to the mammal in combination with other therapeutic agents such as anti-cancer agents. It is believed that the antagonists can be used to block binding of HGF to HGF receptor(s) or substantially prevent HGF receptor activation, tiiereby treating patiiologic conditions associated with binding of HGF to HGF receptor(s) or with die activation of HGF receptor(s). BRIEF DESCRIPTION OF THE DRAWINGS Figures 1 A and IB show die amino acid sequences (and encoding nucleotides) for die light chain (Fig. IA) and heavy chain (Fig. IB), respectively, of monoclonal antibody 5D5 Fab. Figure 2 is a graph showing die inhibition of HGF binding to c-Met-IgG fusion protein by monoclonal antibody 1A3.3.13. Figure 3 is a bar diagram showing the stimulatory effect of monoclonal antibodies 3D6, 6G1, and 1 A3.3.13 on human mammary epithelial cells in a proliferation assay. Figure 4 is a bar diagram showing die stimulatory effect of monoclonal antibodies 3D6, 05-237 and 05- 238 on mink lung cells in a proliferation assay. Figure 5 is a bar diagram showing the inhibitory effect of monoclonal antibody 1 A3.3.13 Fab fragments on BaF3-hmet.8 cells in a proliferation assay. Figures 6A and 6B are FACS analysis graphs showing binding specificity of monoclonal antibody 5D5 to BaF3-hmet.8 cells expressing c-Met. Figure 7 is a graph showing the inhibition of HGF binding to c-Met-IgG fusion protein by monoclonal antibody 5D5 and by 5D5 Fab. Figures 8A and 8B are graphs showing die inhibitory effect of 5D5 Fab on BaF3-hmet.8 cells in a proliferation assay. Figure 9 is a graph showing the inhibitory effect of 5D5 Fab on a human breast carcinoma cell line (MDA-MB-435) which expresses c-Met. Figures 10A and 10B are bar diagrams showing die inhibitory effect of 5D5 Fab on c-Met tyrosine phosphorylation. Figures 11A-I IC are graphs comparing inhibitory effects of NK1 (Fig. 1 IA), 5D5 Fab (Fig. 1 IB), and 5D5 Fab and rhuHGF (Fig. 1 IC) on BaF3-hmet.8 cells in a proliferation assay conducted in the presence or absence of heparin. Figure 12 is a restriction map of plasmid p5D5 containing die discistronic operon for expression of die chimer 5D5 Fab. Figure 13 is a graph showing the inhibition of HGF binding to c-Met-IgG fusion protein by recombinant 5D5 Fab. Figures 14A-14D are graphs comparing me inhibitory effect of recombinant 5D5 Fab and recombinant anti-VEGF Fab (control Fab) on BaF3-hmet.8 cells in a proliferation assay conducted in die presence or absence of heparin. DETAILED DESCRIPTION OF THE INVENTION I. Definitions As used herein, die terms "hepatocyte growdi factor" and "HGF" refer to a growth factor typically having a structure witi six domains (finger, Kringle 1, Kringle 2, Kringle 3, Kringle 4 and serine protease domains) and having the property of binding to a HGF receptor, as defined below. The terms "hepatocyte growth factor" and "HGF" include hepatocyte growui factor from humans ("huHGF") and any non- human mammalian species, and in particular rat HGF. The terms as used herein include mature, pre, pre-pro, and pro forms, purified or isolated from a natural source, chemically synthesized or recombinantly produced. Human HGF is encoded by die cDNA sequence published by Miyazawa et al., 1989, supra, or Nakamura et al., 1989, supra. The sequences reported by Miyazawa et al. and Nakamura et al. differ in 14 amino acids. The reason for die differences is not entirely clear; polymoφhism or cloning artifacts are among the possibilities. Bo i sequences are specifically encompassed by die foregoing terms. It will be understood that natural allelic variations exist and can occur among individuals, as demonstrated by one or more amino acid differences in the amino acid sequence of each individual. The HGF of die invention preferably has at least about 80% sequence identity, more preferably at least about 90% sequence identity, and even more preferably, at least about 95% sequence identity witii a native mammalian HGF. The terms "hepatocyte growui factor" and "HGF" specifically include die delta5 huHGF as disclosed by Seki et al., supra. . The terms "HGF receptor" and "c-Met" when used herein refer to a cellular receptor for HGF, which typically includes an extracellular domain, a transmembrane domain and an intracellular domain, as well as variants and fragments diereof which retain me ability to bind HGF. The terms "HGF receptor" and "c-Met" include die polypeptide molecule that comprises die full-length, native amino acid sequence encoded by the gene variously known as pl90 . The present definition specifically encompasses soluble forms of HGF receptor, and HGF receptor from natural sources, synthetically produced in vitro or obtained by genetic manipulation including meuiods of recombinant DNA technology. The HGF receptor variants or fragments preferably share at least about 65% sequence identity, and more preferably at least about 75% sequence identity with any domain of e human c-Met amino acid sequence published in Rodrigues et al., Mol. Cell. Biol..11:2962-2970 (1991); Park et al., Proc. Natl. Acad. Sci.. £4:6379-6383 (1987); or Ponzetto et al., Oncogene. 6:553-559 (1991). The term "5D5 Fab" is used herein to refer to polypeptide comprising amino acid residues 1 to 220 of the amino acid sequence shown in Figure 1 A (SEQ ID NO: 1 ) and amino acid residues 1 to 230 of die amino acid sequence shown in Figure IB (SEQ ID NO:2), as well as biologically active deletional, insertional, or substitutional variants thereof. In a preferred embodiment, the 5D5 Fab consists of die amino acid sequences shown in Figures 1 A and IB, which correspond to die light chain and heavy chain, respectively, of monoclonal antibody 5D5 Fab. In another preferred embodiment, the biologically active variants have at least about 80% sequence identity, more preferably at least about 90% sequence identity, and even more preferably, at least about 95% sequence identity widi die sequences described above. The definition encompasses 5D5 Fab obtained from an antibody source, such as papain digestion of monoclonal antibody 5D5 described herein, or prepared by recombinant or synthetic methods, described for instance in Example 13 below. The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising HGF receptor antagonist, or a portion diereof, fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere widi activity of die antagonist. The tag polypeptide preferably also is fairly unique so that d e antibody does not substantially cross-react wid other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 to about 50 amino acid residues (preferably, between about 10 to about 20 residues). As used herein, die term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG j , IgG2, IgG 3 , or IgG^) mat is responsible for increasing die in vivo half-life of the IgG molecule. "Isolated," when used to describe die various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials mat would typically interfere with diagnostic or therapeutic uses for die polypeptide, and may include enzymes, hormones, and other proteinaceous or non- proteinaceous solutes. In preferred embodiments, die polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide in situ widiin recombinant cells, since at least one component of die HGF receptor antagonist natural environment will not be present. Ordinarily, however, isolated polypeptide wilj be prepared by at least one purification step. Homogeneity here means less than about 5% contamination widi otiier source proteins and polypeptides. An "isolated" HGF receptor antagonist nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of die HGF receptor antagonist nucleic acid. An isolated HGF receptor antagonist nucleic acid molecule is odier than in the form or setting in which it is found in nature. Isolated HGF receptor antagonist nucleic acid molecules therefore are distinguished from the HGF receptor antagonist nucleic acid molecule as it exists in natural cells. However, an isolated HGF receptor antagonist nucleic acid molecule includes HGF receptor antagonist nucleic acid molecules contained in cells diat ordinarily express HGF receptor antagonist where, for example, die nucleic acid molecule is in a chromosomal location different from that of natural cells. The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein mat participates in the secretion of die polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects die transcription of die sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means diat die DNA sequences being linked are contiguous, and, in die case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, die syndietic oligonucleotide adaptors or linkers are used in accordance widi conventional practice. The terms "amino acid" and "amino acids" refer to all naturally occurring L-α-amino acids. This definition is meant to include norleucine, ornidiine, and homocysteine. The amino acids are identified by either the single-letter or three-letter designations: Asp D aspartic acid He I isoleucine Thr T direonine Leu L leucine Ser S serine Tyr Y tyrosine Glu E glutamic acid Phe F phenylalanine Pro P proline His H histidine Gly G glycine Lys K lysine Ala A alanine Arg R arginine Cys C cysteine Tφ W tryptophan Val V valine Gin Q glutamine Met M mediionine Asn N asparagine In the Sequence Listing and Figures, certain odier single-letter or three-letter designations are employed to refer to and identify two or more amino acids at a given position in the amino acid sequence. For instance, at amino acid residue 1 in SEQ ID NO:2, die diree-letter designation "Glx" is employed to identify diat at residue 1, die amino acid may be a glutamine or a glutamic acid residue. Nucleotide bases referred to in die Sequence Listing and Figures include "A" (adenine), "C" (cytosine), "G" (guanine), "T" (thymine) and "S" (cytosine or guanine). The term "heparin" is used in a broad sense and refers to a heterogeneous group of sulfated, straight-chain anionic mucopolysaccharides, often referred to as glycosaminoglycans. Although others may be present, the main sugars in heparin are: α-L-iduronic acid 2-sulfate, 2-deoxy-2-sulfamino-α-glucose 6-sulfate, β-D-glucuronic acid, 2-acetamido-2-deoxy-α-D-glucose, and L-iduronic acid. These and optionally otiier sugars are typically joined by glycosidic linkages. The molecular weight of heparin typically varies from about 6,000 to about 20,000 Da depending on die source and the method of molecular weight determination. Heparin is a native constituent of various cells and tissues, especially liver and lung, in several mammalian species. The term "heparin-independent" when used herein describes HGF receptor antagonists which have substantially reduced ability to bind heparin or are unable to bind heparin, or heparin-like glycosaminoglycans, including heparan sulfate and proteoglycans. Determination of whether a HGF receptor antagonist is heparin-independent can be determined by die skilled artisan without undue experimentation. Heparin-independence can be determined, for example, by assaying the antagonist for HGF blocking activity in die presence of heparin, as described in die Examples, and observing die activity of the molecule. The terms "agonist" and "agonistic" when used herein refer to or describe a molecule which is capable of, directly or indirectly, substantially inducing, promoting or enhancing HGF biological activity or HGF receptor activation. The terms "antagonist" and "antagonistic" when used herein refer to or describe a molecule which is capable of, directly or indirectly, substantially counteracting, reducing or inhibiting HGF biological activity or HGF receptor activation. The term "HGF biological activity" when used herein refers to any mitogenic, motogenic or moφhogenic activities of HGF or any activities occurring as a result of HGF binding to a HGF receptor. The term "HGF receptor activation" refers to HGF receptor dimerization or HGF receptor-induced tyrosine kinase activity. HGF receptor activation may occur as a result of HGF binding to a HGF receptor, but may alternatively occur independent of any HGF binding to a HGF receptor. HGF biological activity may, for example, be determined in an in vitro or in vivo assay of hepatocyte growth promotion. Adult rat hepatocytes in primary culture have been used to test the effect of HGF on hepatocyte proliferation. Accordingly, the effect of a HGF receptor antagonist can be determined in an assay suitable for testing die ability of HGF to induce DNA syndiesis of rat hepatocytes in primary cultures. Human hepatocytes can be cultured similarly to the methods established for preparing primary cultures of normal rat hepatocytes. Alternatively, the effect of a HGF receptor antagonist can be determined in an assay suitable for testing die ability of HGF to induce DNA syndiesis in other types of cells expressing HGF receptor(s), such as mink lung cells or human mammary epitiielial cells described in Examples 4 and 5. DNA syndiesis can, for example, be assayed by measuring incoφoration of 3 H-thymidine into DNA. The effectiveness of die HGF receptor antagonist can be determined by its ability to block proliferation and incoφoration of the 3 H-uιymidine into DNA. The effect of HGF receptor antagonists can also be tested in vivo in animal models. The term "antibody" is used herein in a broad sense and includes intact immunoglobulin or antibody molecules, polyclonal antibodies, multispecific antibodies (i.e., bispecific antibodies formed from at least two intact antibodies) and immunoglobulin fragments (such as Fab, F(ab')2 > or Fv), so long as they exhibit any of die desired antagonistic properties described herein. Antibodies are typically proteins or polypeptides which exhibit binding specificity to a specific antigen. Native antibodies are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V j ) followed by a number of constant domains. Each light chain has a variable domain at one end (V j and a constant domain at its other end; die constant domain of the light chain is aligned with the first constant domain of the heavy chain, and die light chain variable domain is aligned widi die variable domain of die heavy chain. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains [Chothia et al., J. Mol. Biol..1£6:651-663 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. USA. 82:4592- 4596 (1985)]. The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (K) and lambda (λ), based on ie amino acid sequences of dieir constant domains. Depending on die amino acid sequence of die constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of tiiese may be further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. The heavy chain constant domains mat correspond to die different classes of immunoglobulins are called α, delta, epsilon, γ, and μ, respectively. "Antibody fragments" comprise a portion of an intact antibody, generally die antigen binding or variable region of tiie intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, single chain antibody molecules, and multispecific antibodies formed from antibody fragments. The term "variable" is used herein to describe certain portions of die variable domains which differ in sequence among antibodies and are used in die binding and specificity of each particular antibody for its particular antigen. However, die variability is not usually evenly disfributed dirough die variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a β-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, die β-sheet structure. The CDRs in each chain are held togedier in close proximity by die FR regions and, widi die CDRs from die other chain, contribute to the formation of the antigen binding site of antibodies [see Kabat, E.A. et al., Sequences of Proteins of Immunological Interest. National Institutes of Healdi, Bediesda, MD (1987)]. The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of die antibody in antibody-dependent cellular toxicity. The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., die individual antibodies comprising the population are identical except for possible naturally occurring mutations diat may be present in minor amounts. The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of die heavy and/or light chain is identical widi or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of die chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to ano er antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired antagonistic activity [U.S. Patent No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA. 81:6851-6855 (1984)]. The terms "cancer" and "cancerous" when used herein refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, sarcoma, blastoma and leukemia. More particular examples of such cancers include squamous cell carcinoma, lung cancer (small cell and non-small cell), gastrointestinal cancer, liver cancer, kidney cancer, pancreatic cancer, cervical cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, and head and neck cancer. While die term "cancer" as used herein is not limited to any one specific form of die disease, it is believed diat die mediods of die invention will be particularly effective for cancers which are found to be accompanied by increased levels of HGF or overexpression or activation of HGF receptor in die mammal. The terms "treating," "treatment," and "therapy" as used herein refer to curative therapy, prophylactic therapy, and preventative therapy. The term "mammal" as used herein refers to any animal classified as a mammal, including humans, cows, horses, dogs and cats. In a preferred embodiment of die invention, die mammal is a human. II. Compositions and Methods of the Invention In one embodiment of die invention, HGF receptor antagonists are provided. Non-limiting examples of HGF receptor antagonists include antibodies, polypeptides, glycoproteins, glycopeptides, glycolipids, polysaccharides, oligosaccharides, nucleic acids, bioorganic molecules, peptidomimetics, pharmacological agents and tiieir metabolites, transcriptional and translation control sequences, and die like. A. Antibody Compositions In one embodiment of invention, die HGF receptor antagonists of the invention comprise HGF receptor antibodies. For instance, die antagonist antibodies may be polyclonal antibodies. Methods of preparing polyclonal antibodies are known to die skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in die mammal by multiple subcutaneous or intraperitoneal injections. Preferably, the immunizing agent includes die c-Met polypeptide or a fusion protein diereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins which may be employed include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean rrypsin inhibitor. An aggregating agent such as alum may also be employed to enhance die mammal's immune response. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation. The mammal can then be bled, and die serum assayed for HGF receptor antibody titer. If desired, die mammal can be boosted until the antibody titer increases or plateaus. The antagonist antibodies of the invention may, alternatively, be monoclonal antibodies. Antagonist monoclonal antibodies of die invention may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature.2≤6:495 (1975). In a hybridoma method, a mouse or other appropriate host animal, is typically immunized (such as described above) with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. Preferably, the immunizing agent includes die c-Met polypeptide or a fusion protein thereof. The immunizing agent may alternatively comprise a fragment or portion of HGF or a HGF receptor having one or more amino acid residues diat participate in die binding of HGF to its receptor. In a more preferred embodiment, die immunizing agent comprises an extracellular domain of c-Met fused to an IgG sequence, such as described in Example 1. Generally, eidier peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused widi an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice. Academic Press, ( 1986) pp.59- 103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit die growtii or survival of d e unfused, immortalized cells. For example, if die parental cells lack the enzyme hypoxanthine guanine phosphoribosyl txansferase (HGPRT or HPRT), die culture medium for d e hybridomas typically will include hypoxandiine, aminopterin, and u ymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are tiiose mat fuse efficiently, support stable high level expression of antibody by die selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Rockville, Maryland. An example of such a murine myeloma cell line is P3X63AgU.l, described in Example 1 below. Human myeloma and mouse-human heteromyeloma cell lines also have been described for die production of human monoclonal antibodies [Kozbor, J. Immunol..111:3001-3005 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications. Marcel Dekker, Inc., New York, (1987) pp. 51-63]. The culture medium in which die hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against a HGF receptor. Preferably, the binding specificity of monoclonal antibodies produced by die hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art, and are described further in the Examples below. The binding affinity of die monoclonal antibody can, for example, be determined by die Scatchard analysis of Munson and Pollard, Anal. Biochem..1122:220-239 (1980). After die desired hybridoma cells are identified, die clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, sup a . Suitable culture media for this puφose include, for example, Dulbecco's Modified Eagle's Medium and RPMI- 1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal. The monoclonal antibodies secreted by the subclones may be isolated or purified from die culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding die monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of die invention serve as a preferred source of such DNA. Once isolated, die DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, E. coli. Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the syndiesis of monoclonal antibodies in die recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of e homologous murine sequences [U.S. Patent No.4,816,567; Morrison et al., supra] or by covalently joining to the immunoglobulin coding sequence all or part of die coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for die constant domains of an antibody of die invention, or can be substituted for die variable domains of one antigen-combining site of an antibody of die invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for a HGF receptor and anodier antigen-combining site having specificity for a different antigen, such as HER2 or CD3. It is believed, however, mat monovalent antibodies capable of binding to a HGF receptor will be especially useful as HGF receptor antagonists. While not being bound to any particular theory, it is presently believed that activation of c-Met may proceed by a mechanism wherein huHGF binding to c-Met induces aggregation or dimerization of die receptors which in turn activates intracellular receptor kinase activity. Because monovalent antibodies will likely be unable to induce such aggregation or dimerization, die monovalent antibodies should not activate c-Met. Such monovalent antibodies may be directed against die HGF binding site of die receptor or may odierwise be capable of interfering widi HGF, its fragments or its variants binding to die HGF receptor, such as by sterically hindering HGF, its fragments or its variants access to the receptor. Alternatively, die monovalent antibodies may be capable of sterically preventing HGF receptor dimerization. Methods for preparing monovalent antibodies are well known in die art. For example, one mediod involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues may be substituted widi anodier amino acid residue or are deleted so as to prevent crosslinking. Recombinant expression of Fab light chain and heavy chain is described in further detail below. In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments diereof, particularly, Fab fragments, can be accomplished using routine techniques known in die art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published 12/22/94 and U.S. Patent No. 4,342,566. Papain digestion is also described in Examples 6 and 7 below. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields an F(ab') 7 fragment mat has two antigen combining sites and is still capable of cross-linking antigen. The Fab fragments produced in die antibody digestion also contain the constant domains of die light chain and die first constant domain (CH j ) of die heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at die carboxy terminus of die heavy chain CH j domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab 1 in which the cysteine residue(s) of die constant domains bear a free thiol group. F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known. In a preferred embodiment of die invention, the antagonists comprise Fab fragments of monoclonal antibodies specific for c-Met. In a more preferred embodiment, the monoclonal antibody Fab fragments have die same biological characteristics as the monoclonal antibody Fab fragments produced by digesting either of die monoclonal antibodies secreted by the hybridoma cell lines deposited under American Type Culture Collection Accession Nos. ATCC HB- 11894 or ATCC HB- 11895. The term "biological characteristics" is used to refer to die in vitro and/or in vivo activities of die monoclonal antibody, e.g., ability to substantially reduce or inhibit binding of huHGF to c-Met or to substantially reduce or inhibit c-Met activation. Accordingly, die monovalent antibody preferably binds to substantially die same epitope as the 1 A3.3.13 antibody or die 5D5.11.6 antibody disclosed herein. This can be determined by conducting assays described herein and in die Examples. For instance, to determine whether a monoclonal antibody has the same specificity as die 1 A3.3.13 antibody specifically disclosed (i.e., die antibody having die ATCC deposit No. HB- 11894) or the 5D5.11.6 antibody specifically disclosed (i.e., die antibody having the ATCC deposit No. HB- 11895), one can use a competitive ELISA binding assay such as tiiose described in die Examples. In an even more preferred embodiment, die monoclonal antibody Fab fragments are heparin-independent antagonists, as defined herein. In a preferred embodiment of the invention, die monoclonal antibody or fragment thereof will inhibit die binding of HGF, its fragments or its variants, or die mitogenic activity of HGF, its fragments, or its variants at least about 50%, preferably, greater than about 80%, and more preferably, greater than about 90%, as determined by an in vitro competitive binding assay or proliferation assay, such as described in die Examples below. In addition to die antagonist antibodies described above, it is contemplated that chimeric or hybrid antagonist antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a diioedier bond. Examples of suitable reagents for this puφose include iminodiiolate and methyl-4-mercaptobutyrimidate. The antagonist antibodies of die invention may also comprise diabodies. The term "diabodies" refers to small antibody fragments widi two antigen binding sites, which fragments comprise a heavy chain variable domain (VJJ) connected to a light chain variable domain (V L ) in die same polypeptide chain (V^ - V L ). By using a linker that is too short to allow pairing between die two domains on die same chain, die domains are forced to pair with die complementary domains of anodier chain and create two antigen binding sites. Diabodies are described in further detail, for example, in EP 404,097; WO 93/11161 ; and Hollinger et al., Proc. Natl. Acad. Sci..20:6444-6448 (1993). The antagonist antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments diereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of die recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of die human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to tiiose of a non-human immunoglobulin and all or substantially all of the FR regions are diose of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature.121:522-525 (1986); Reichmann et al., Nature.112:323-327 (1988); and Presta, Curr. Op. Struct. BJa 2:593-596 (1992)]. Methods for humanizing non-human antibodies are well known in die art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following die method of Winter and co-workers [Jones et al., Nature.121:522-525 (1986); Riechmann et al., Nature.112:323-327 (1988); Verhoeyen et al., Science.239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. The choice of human variable domains, botii light and heavy, to be used in making the humanized antibodies is important in order to reduce antigenicity. According to the "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against die entire library of known human variable domain sequences. The human sequence which is closest to that of the rodent is ti en accepted as the human framework (FR) for the humanized antibody [Sims et al., J. Immunol..151:2296 (1993); Chothia and Lesk, J. Mol. Biol..126:901 (1987)]. Anodier mediod uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies [Carter et al., Proc. Natl. Acad. Sci. USA. £2:4285 ( 1992); Presta et al., J. Immunol..111:2623-2632 (1993)]. It is further important mat antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred mediod, humanized antibodies are prepared by a process of analysis of die parental sequences and various conceptual humanized products using three dimensional models of die parental and humanized sequences. Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of die candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so diat die desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, die CDR residues are directly and most substantially involved in influencing antigen binding [see, WO 94/04679 published 3 March 1994]. Transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described diat die homozygous deletion of die antibody heavy chain joining region (J H ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of die human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge [see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA. 20:2551-255 (1993); Jakobovits et al., Nature.162:255-258 (1993); Bruggermann et al., Year in Immuno..2:33 (1993)]. Human antibodies can also be produced in phage display libraries [Hoogenboom and Winter, J. Mol. Biol..227:381 (1991); Marks et al., J. Mol. Biol. 222:581 (1991)]. The techniques of Cote et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol.. 147(H:86-95 (1991)]. B. Polypeptides and Nucleic Acid Compositions The present invention also provides HGF receptor antagonists comprising one or more isolated polypeptides. In one embodiment, the antagonist comprises residues 1 to 220 of d e amino acid sequence shown in Figure IA (SEQ ID NO:l) and residues 1 to 230 of die amino acid sequence shown in Figure IB (SEQ ID NO:2). Preferably, die antagonist comprises two isolated polypeptides which correspond to the light chain and heavy chain, respectively, of an anti-HGF receptor monoclonal antibody Fab. 1. Preparation of HGF Receptor Antagonist The description below relates primarily to production of die HGF receptor antagonist by culturing cells transformed or transfected widi a vector containing the antagonist nucleic acid and recovering die polypeptide(s) from die cell culture. It is of course, contemplated diat alternative methods, which are well known in the art, may be employed to prepare the HGF receptor antagonist polypeptide. 1. Isolation of DNA Encoding HGF Receptor Antagonist The DNA encoding die HGF receptor antagonist may be obtained from any cDNA library prepared from tissue believed to possess die antagonist mRNA and to express it at a detectable level. Accordingly, human c-Met antagonist DNA can be conveniently obtained from a cDNA library prepared from human tissues. The c-Met antagonist-encoding gene may also be obtained from a genomic library or by oligonucleotide synthesis. Libraries can be screened widi probes (such as antibodies to the c-Met receptor antagonist or oiigonucleotides of at least about 20-80 bases) designed to identify die gene of interest or die protein encoded by it. Screening die cDNA or genomic library widi die selected probe may be conducted using standard procedures, such as described in Sambrook et al.. Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding the receptor antagonist is to use PCR methodology [Sambrook et al., supra: Dieffenbach et al., PCR Primer:A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)]. One mediod of screening employs selected oligonucleotide sequences to screen cDNA libraries from various human tissues. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such diat it can be detected upon hybridization to DNA in die library being screened. Mediods of labeling are well known in die art, and include die use of radiolabels like 32 P-labeled ATP, biotinylation or enzyme labeling. Nucleic acid having all the protein coding sequence may be obtained by screening selected cDNA or genomic libraries using die amino acid sequence disclosed herein, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA mat may not have been reverse-transcribed into cDNA. Amino acid sequence variants of ie antagonist polypeptide can be prepared by introducing appropriate nucleotide changes into its DNA, or by synthesis of the desired antagonist polypeptide. Such variants represent insertions, substitutions, and/or deletions of residues widiin or at one or bodi of die ends of die amino acid sequences shown in Figures 1 A and IB for die 5D5 Fab. Any combination of insertion, substitution, and/or deletion can be made to arrive at the final construct, provided diat die final construct possesses the desired antagonistic activity as defined herein. In a preferred embodiment, die variants have at least about 80% sequence identity, more preferably, at least about 90% sequence identity, and even more preferably, at least about 95% sequence identity widi die sequences identified herein for die 5D5 Fab. Variations in the native sequence as described above can be made using any of die techniques and guidelines for conservative and non-conservative mutations set forth in U.S. Pat. No. 5,364,934. These include oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. 2. Insertion of Nucleic Acid into A Replicable Vector The nucleic acid (e.g., cDNA or genomic DNA) encoding the receptor antagonist may be inserted into a replicable vector for further cloning (amplification of die DNA) or for expression. Various vectors are publicly available. The vector components generally include, but are not limited to, one or more of die following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, each of which is described below. (i) Signal Sequence Component The HGF receptor antagonist may be produced recombinantly not only directly, but also as a fusion polypeptide widi a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of die antagonist DNA that is inserted into die vector. The heterologous signal sequence selected preferably is one diat is recognized and processed (i.e., cleaved by a signal peptidase) by die host cell. The signal sequence may be a prokaryotic signal sequence selected, for example, from die group of die alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., die yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces α-factor leaders, die latter described in U.S. Pat. No. 5,010,182), or acid phosphatase leader, die C. albicans glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of die same or related species, as well as viral secretory leaders, for example, the heφes simplex glycoprotein D signal. The DNA for such precursor region is preferably ligated in reading frame to DNA encoding die antagonist. (ifi Origin of Replication Component Bom expression and cloning vectors contain a nucleic acid sequence diat enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of die host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, die origin of replication component is not needed for mammalian expression vectors (die SV40 origin may typically be used because it contains the early promoter). Most expression vectors are "shuttle" vectors, i.e., tiiey are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in E. coli and then die same vector is transfected into yeast or mammalian cells for expression even tiiough it is not capable of replicating independently of die host cell chromosome. DNA may also be amplified by insertion into die host genome. This is readily accomplished using Bacillus species as hosts, for example, by including in die vector a DNA sequence diat is complementary to a sequence found in Bacillus genomic DNA. Transfection of Bacillus with this vector results in homologous recombination widi die genome and insertion of die receptor antagonist DNA. However, the recovery of genomic DNA encoding die antagonist is more complex man diat of an exogenously replicated vector because restriction enzyme digestion is required to excise die antagonist DNA. (iii) Selection Gene Component Expression and cloning vectors typically contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed widi die vector containing the selection gene will not survive in die culture medium. Typical selection genes encode proteins diat (a) confer resistance to antibiotics or otiier toxins, e.g., ampicillin, neomycin, metiiotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli. One example of a selection scheme utilizes a drug to arrest growtii of a host cell. Those cells diat are successfully transformed widi a heterologous gene produce a protein conferring drug resistance and dius survive die selection regimen. Examples of such dominant selection use die drugs neomycin [Southern et al., J. Molec. Appl. Genet. 1:327 (1982)], mycophenolic acid (Mulligan et al., Science. 202:1422 (1980)] or hygromycin [Sugden et al., Mol. Cell. Biol.. 5:410-413 (1985)]. The three examples given above employ bacterial genes under eukaryotic control to convey resistance to die appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin. respectively. Another example of suitable selectable markers for mammalian cells are those diat enable the identification of cells competent to take up die antagonist nucleic acid, such as DHFR or thymidine kinase. The mammalian cell transformants are placed under selection pressure that only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in die medium is successively changed, tiiereby leading to amplification of botii the selection gene and the DNA diat encodes the receptor antagonist. Amplification is die process by which genes in greater demand for die production of a protein critical for growth are reiterated in tandem within die chromosomes of successive generations of recombinant cells. Other examples of amplifiable genes include metallotiiionein-I and -II, adenosine deaminase, and ornithine decarboxylase. Cells transformed widi die DHFR selection gene may first be identified by culturing all of die transformants in a culture medium diat contains metiiotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is die Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA.22:4216 (1980). The transformed cells are then exposed to increased levels of mediotrexate. This leads to die synthesis of multiple copies of die DHFR gene, and, concomitantly, multiple copies of otiier DNA comprising die expression vectors, such as die DNA encoding die receptor antagonist. This amplification technique can be used widi any otherwise suitable host, e.g, ATCC No. CCL61 CHO-Kl, notwithstanding die presence of endogenous DHFR if, for example, a mutant DHFR gene mat is highly resistant to Mtx is employed (EP 117,060). Alternatively, host cells (particularly wild-type hosts diat contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding HGF receptor antagonist, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3'-phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminogiycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Patent No. 4,965,199. A suitable selection gene for use in yeast is the trpl gene present in die yeast plasmid YRp7 [Stinchcomb et al., Nature.282:39 (1979); Kingsman et al., Gene.2:141 (1979); Tschemper et al., Gene.10:157 (1980)]. The trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No.44076 or PEP4-1 [Jones, Genetics. £5:12 (1977)]. The presence of the trpl lesion in the yeast host cell genome men provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, eu2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing die Leul gene. In addition, vectors derived from die 1.6 μm circular plasmid pKDl can be used for transformation of Kiuyveromyces yeasts [Bianchi et al., Curr. Genet.. 12:185 (1987)]. More recently, an expression system for large-scale production of recombinant calf chymosin was reported for K. lactis [Van den Berg, Bio/Technologv. £: 135 (1990)]. Stable multi-copy expression vectors for secretion of mature recombinant human serum albumin by industrial strains of Kiuyveromyces have also been disclosed [Fleer et al., Bio/Technology.2:968-975 ( 1991 )]. (iv) Promoter Component Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the receptor antagonist nucleic acid sequence. Promoters are untranslated sequences located upstream (5') to d e start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of particular nucleic acid sequence to which they are operably linked. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters mat initiate increased levels of transcription from DNA under tiieir control in response to some change in culture conditions, e.g., die presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably linked to receptor antagonist encoding DNA by removing die promoter from the source DNA by restriction enzyme digestion and inserting die isolated promoter sequence into die vector. Various heterologous promoters may be used to direct amplification and or expression of the receptor antagonist DNA. Promoters suitable for use widi prokaryotic hosts include die β-Iactamase and lactose promoter systems [Chang et al., Nature.225:615 (1978); Goeddel et al., Nature.2£i:544 (1979)], alkaline phosphatase, a tryptophan (tip) promoter system [Goeddel, Nucleic Acids Res.. £:4057 (1980); EP 36,776], and hybrid promoters such as die tac promoter [deBoer et al, Proc. Natl. Acad. Sci. USA. £0_:21-25 (1983)]. However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate diem to DNA encoding receptor antagonist [Siebenlist et al., Cell.22:269 (1980)] using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also will contain a Shine-Dalgamo (S.D.) sequence operably linked to die DNA encoding HGF receptor antagonist. Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from die site where transcription is initiated. At die 3' end of most eukaryotic genes is an AATAAA sequence diat may be die signal for addition of die poly A tail to die 3' end of die coding sequence. All of tiiese sequences are suitably inserted into eukaryotic expression vectors. Examples of suitable promoting sequences for use widi yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem..255:2073 (1980)] or otiier glycolytic enzymes [Hess et al., J. Adv. Enzvme Reg.. 2:149 (1968); Holland, Biochemistry. 12:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose- 6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other yeast promoters, which are inducible promoters having die additional advantage of transcription controlled by growth conditions, are die promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated widi nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Yeast enhancers also are advantageously used widi yeast promoters. HGF receptor antagonist transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from die genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), or from heterologous mammalian promoters, e.g, die actin promoter or an immunoglobulin promoter, from heat-shock promoters, provided such promoters are compatible with the host cell systems. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains die SV40 viral origin of replication [Fiers et al., Nature. 273: 1 13 (1978); Mulligan and Berg, Science.209: 1422-1427 (1980); Pavlakis et al., Proc. Natl. Acad. Sci. USA.2£:7398-7402 (1981)]. The immediate early promoter of die human cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment [Greenaway et al., Gene. l£:355-360 (1982)]. A system for expressing DNA in mammalian hosts using die bovine papilloma virus as a vector is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978 [See also Gray et al., Nature. 225:503-508 (1982) on expressing cDNA encoding immune interferon in monkey cells; Reyes et al., Nature.222:598-601 (1982) on expression of human β-interferon cDNA in mouse cells under die control of a tiiymidine kinase promoter from heφes simplex virus; Canaani and Berg. Proc. Natl. Acad. Sci. USA 79:5166-5170 (1982) on expression of the human interferon β 1 gene in cultured mouse and rabbit cells; and Gorman et al., Proc. Natl. Acad. Sci. USA. 22:6777-6781 (1982) on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using die Rous sarcoma virus long terminal repeat as a promoter]. (v) Enhancer Element Component Transcription of a DNA encoding die HGF receptor antagonist of this invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, at act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent, having been found 5' [Laimins et al., Proc. Natl. Acad. Sci. USA.2£:993 (1981]) and 3' [Lusky et al., Mol. Cell Bio..1:1108 (1983]) to the transcription unit, widiin an intron [Banerji et al., Cell.11:729 (1983)], as well as within die coding sequence itself [Osbome et al., Mol. Cell Bio.. 4:1293 (1984)]. Many enhancer sequences are now known from mammalian genes (globin, elastase. albumin, α-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include die SV40 enhancer on the late side of die replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, die polyoma enhancer on die late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature. 297:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into die vector at a position 5' or 3' to the HGF receptor antagonist-encoding sequence, but is preferably located at a site 5' from the promoter, (vi) Transcription Termination Component Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding HGF receptor antagonist. (vii) Construction and Analysis of Vectors Construction of suitable vectors containing one or more of the above-listed components employs standard ligation techniques, isolated plasmids or DNA fragments are cleaved, tailored, and re-ligated in die form desired to generate the plasmids required. For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures can be used to transform E. coli K12 sfrain 294 (ATCC 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion, and/or sequenced by die mediod of Messing et al., Nucleic Acids Res.. 9:309 (1981) or by the method of Maxam et al., Methods in Enzvmologv.65:499 (1980). (viii) Transient Expression Vectors Expression vectors diat provide for die transient expression in mammalian cells of DNA encoding HGF receptor antagonist may be employed. In general, transient expression involves the use of an expression vector diat is able to replicate efficiently in a host cell, such that die host cell accumulates many copies of e expression vector and, in turn, syntiiesizes high levels of a desired polypeptide encoded by the expression vector [Sambrook et al., supra]. Transient expression systems, comprising a suitable expression vector and a host cell, allow for die convenient positive identification of polypeptides encoded by cloned DNAs, as well as for die rapid screening of such polypeptides for desired biological or physiological properties. Thus, transient expression systems are particularly useful in the invention for puφoses of identifying analogs and variants of die receptor antagonists. (ix Suitable Exemplary Vertebrate Cell Vectors Other methods, vectors, and host cells suitable for adaptation to die syndiesis of HGF receptor antagonist in recombinant vertebrate cell culture are described in Getiiing et al., Nature. 221:620-625 (1981); Mantei et al., Nature.2M-40-46 (1979); EP 117,060; and EP 117,058. 3. Selection and Transformation of Host Cells Suitable host cells for cloning or expressing the DNA in die vectors herein are die prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes for this piupose include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710 published 12 April 1989), Pseudomonas such as P. aeruginosa, and Streptomyces. Preferably, die host cell should secrete minimal amounts of proteolytic enzymes. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for HGF receptor antagonist-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is die most commonly used among lower eukaryotic host microorganisms. However, a number of otiier genera, species, and strains are commonly available and useful herein. Suitable host cells for the expression of glycosylated HGF receptor antagonist are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodopterafrugiperda (cateφillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfiy), and Bombyx mori have been identified [See, e.g., Luckow et al., Bio/Technologv. 6:47-55 (1988); Miller et al., in Genetic Engineering. Setlow et al., eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda et al., Nature. 315:592-594 (1985)]. A variety of viral strains for transfection are publicly available, e.g., the L-l variant of Autographa californica NPV and die Bm-5 strain of Bombyx mori NPV. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts. Typically, plant cells are transfected by incubation widi certain strains of the bacterium Agrobacterium tumefaciens, which has been previously manipulated to contain the receptor antagonist-encoding DNA. During incubation of die plant cell culture widi A. tumefaciens, die DNA encoding die receptor antagonist is transferred to die plant cell host such that it is transfected, and will, under appropriate conditions, express the receptor antagonist-encoding DNA. In addition, regulatory and signal sequences compatible widi plant cells are available, such as the nopaline syntiiase promoter and polyadenylation signal sequences [Depicker et al., J. Mol. Appl. Gen..1:561 (1982)]. In addition, DNA segments isolated from die upstream region of die T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue [EP 321,196 published 21 June 1989]. Propagation of vertebrate cells in culture (tissue culture) is also well known in die art [See, e.g., Tissue Culture. Academic Press, Kruse and Patterson, editors (1973)]. Examples of useful mammalian host cell lines are monkey kidney CVl line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growtii in suspension culture, Graham et al., J. Gen Virol..16:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cellsΛDHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA.22:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod..21:243- 251 (1980)); monkey kidney cells (CVl ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci.. !£i:44-68 (1982)); MRC 5 cells; and FS4 cells. Host cells are transfected and preferably transformed with die above-described expression or cloning vectors for HGF receptor antagonist production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Transfection refers to the taking up of an expression vector by a host cell whetiier or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, CaPO^ and electroporation. Successful transfection is generally recognized when any indication of die operation of this vector occurs witiiin the host cell. Transformation means introducing DNA into an organism so diat die DNA is replicable, eitiier as an extrachromosomal element or by chromosomal integrant. Depending on die host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection widi Agrobacterium tumefaciens is used for transformation of certain plant cells, as described by Shaw et al., Gene.21:315 (1983) and WO 89/05859 published 29 June 1989. In addition, plants may be transfected using ultrasound treatment as described in WO 91/00358 published 10 January 1991. For mammalian cells without such cell walls, die calcium phosphate precipitation method of Graham and van der Eb, Virology.52:456-457 (1978) is preferred. General aspects of mammalian cell host system transformations have been described in U.S. Pat. No.4,399,216. Transformations into yeast are typically carried out according to die method of Van Solingen et al., J. Bact.112:946 ( 1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA).26:3829 (1979), However, otiier metiiods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyomithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzvmologv. l£5:527-537 (1990) and Mansour et al., Nature.116:348-352 (1988). 4. Culturing the Host Cells Prokaryotic cells used to produce HGF receptor antagonist may be cultured in suitable media as described generally in Sambrook et al., supra. The mammalian host cells used to produce HGF receptor antagonist may be cultured in a variety of media. Examples of commercially available media include Ham's F10 (Sigma), Minimal Essential Medium ("MEM", Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ("DMEM", Sigma). Any such media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transfeπin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any otiier necessary supplements may also be included at appropriate concentrations diat would be known to tiiose skilled in die art. The culture conditions, such as temperature, pH, and die like, are tiiose previously used widi die host cell selected for expression, and will be apparent to die ordinarily skilled artisan. In general, principles, protocols, and practical techniques for maximizing the productivity of mammalian cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach. M. Butler, ed. (IRL Press, 1991). The host cells referred to in this disclosure encompass cells in culture as well as cells that are within a host animal. 5. Detecting Gene Amplification/Expression Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Soutiiem blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA. 22:5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Various labels may be employed, most commonly radioisotopes, and particularly P. However, otiier techniques may also be employed, such as using biotin-modified nucleotides for introduction into a polynucleotide. The biotin then serves as die site for binding to avidin or antibodies, which may be labeled widi a wide variety of labels, such as radionucleotides, fluorescers or enzymes. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and die assay may be carried out where die duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected. Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Widi immunohistochemical staining techniques, a cell sample is prepared, typically by dehydration and fixation, followed by reaction widi labeled antibodies specific for die gene product coupled, where die labels are usually visually detectable, such as enzymatic labels, fluorescent labels, or luminescent labels. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be eitiier monoclonal or polyclonal, and may be prepared in any mammal. 6. Purification of HGF Receptor Antagonist Polypeptide HGF receptor antagonist preferably is recovered from the culture medium as a secreted polypeptide, altiiough it also may be recovered from host cell lysates when directly produced witiiout a secretory signal. If the receptor antagonist is membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or its extracellular region may be released by enzymatic cleavage. When die antagonist is produced in a recombinant cell otiier than one of human origin, the antagonist polypeptide is free of proteins or polypeptides of human origin. However, it may be desired to purify die receptor antagonist from recombinant cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to die receptor antagonist. As a first step, die culture medium or lysate may be centrifuged to remove particulate cell debris. HGF receptor antagonist tiiereafter is purified from contaminant soluble proteins and polypeptides, widi die following procedures being exemplary of suitable purification procedures: by fractionation on an ion-exchange column; etiianol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; and protein A Sepharose columns to remove contaminants such as IgG. A protease inhibitor such as phenyl metiiyl sulfonyl fluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent die growth of adventitious contaminants. 7. Covalent Modifications Covalent modifications of HGF receptor antagonists are included within the scope of this invention. One type of covalent modification of die HGF receptor antagonist is introduced into die molecule by reacting targeted amino acid residues of die antagonist with an organic derivatizing agent that is capable of reacting widi selected side chains or the N- or C- terminal residues of die antagonist. Derivatization with bifunctional agents is useful for crosslinking the antagonist to a water- insoluble support matrix or surface for use in a method for purifying. Commonly used crosslinking agents include, e.g., l,l-bis(diazoacetyl)-2-phenyletiiane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters widi 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'- didιiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-l,8-octane. Derivatizing agents such as medιyl-3-[(p-azidophenyl)didιio]propioimidate yield photoactivatable intermediates diat are capable of forming crosslinks in die presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and die reactive substrates described in U.S. Patent Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization. Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties. W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group. The modified forms of the residues fall within the scope of the present invention. Another type of covalent modification of die receptor antagonist polypeptide included within die scope of this invention comprises altering die native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for puφoses herein to mean deleting one or more carbohydrate moieties and/or adding one or more glycosylation sites that are not present in the native polypeptide. Glycosylation of polypeptides is typically eitiier N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-Z-serine and asparagine-Z-direonine, where Z is any amino acid except proline, are die recognition sequences for enzymatic attachment of die carbohydrate moiety to die asparagine side chain. Thus, die presence of eitiier of tiiese tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to die attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxylamino acid, most commonly serine or tiireonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. Addition of glycosylation sites to the polypeptide may be accomplished by altering the amino acid sequence such diat it contains one or more of die above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by die addition of, or substitution by, one or more serine or tiireonine residues to die native sequence (for O-linked glycosylation sites). The amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the polypeptide at preselected bases such diat codons are generated diat will translate into the desired amino acids. The DNA mutation(s) may be made using methods described above and in U.S. Pat. No. 5,364,934, supra. Another means of increasing die number of carbohydrate moieties on the polypeptide is by chemical or enzymatic coupling of glycosides to die polypeptide. Depending on the coupling mode used, the sugars) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as tiiose of cysteine, (d) free hydroxyl groups such as those of serine, tiireonine, or hydroxyproline, (e) aromatic residues such as tiiose of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem.. pp. 259-306 (1981). Removal of carbohydrate moieties present on the polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. For instance, chemical deglycosylation by exposing the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound can result in die cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgaiactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin, et al.. Arch. Biochem. Biophvs.. 259:52 ( 1987) and by Edge et al., Anal. Biochem.. 118: 131 ( 1981 ). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzvmol.. 138:350 (1987L Glycosylation at potential glycosylation sites may be prevented by the use of the compound tunicamycin as described by Duskin et al., J. Biol. Chem..257:3105 ( 1982). Tunicamycin blocks the formation of protein-N-glycoside linkages. Anotiier type of covalent modification comprises linking the HGF receptor antagonist to one of a variety of nonproteinaceous polymers, e.g., polyetiiylene glycol ("PEG"), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. WO 93/00109 also describes methods of linking amino acid residues in polypeptides to PEG molecules. 8. HGF Receptor Antagonist Chimeras The present invention also provides chimeric molecules comprising HGF receptor antagonist fused to anotiier, heterologous polypeptide. In one embodiment, die chimeric molecule comprises a fusion of die antagonist with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at die amino- or carboxyl- terminus of die antagonist. The presence of such epitope-tagged forms of die antagonist can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables die antagonist to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to die epitope tag. Various tag polypeptides and tiieir respective antibodies are well known in the art. Examples include the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol.. £:2159-2165 (1988)]; the c-myc tag and die 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies tiiereto [Evan et al., Molecular and Cellular Biology.5:3610-3616 (1985)]; and die Heφes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering. i(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology.6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science.255:192-194 (1992)]; an α-tubulin epitope peptide [Skinner et al., J. Biol. Chem.. 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA. £2:6393-6397 (1990)]. Once the tag polypeptide has been selected, an antibody thereto can be generated using die techniques disclosed herein. Generally, epitope-tagged antagonist may be constructed and produced according to the methods described above. HGF receptor antagonist-tag polypeptide fusions are preferably constructed by fusing the cDNA sequence encoding die HGF receptor antagonist portion in-frame to die tag polypeptide DNA sequence and expressing die resultant DNA fusion construct in appropriate host cells. Ordinarily, when preparing die HGF receptor antagonist-tag polypeptide chimeras of die present invention, nucleic acid encoding die antagonist will be fused at its 3' end to nucleic acid encoding die N-terminus of the tag polypeptide, however 5' fusions are also possible. For example, a polyhistidine sequence of about 5 to about 10 histidine residues may be fused at die N- terminus or the C- terminus and used as a purification handle in affinity chromatography. Epitope-tagged HGF receptor antagonist can be purified by affinity chromatography using the anti-tag antibody. The matrix to which the affinity antibody is attached may include, for instance, agarose, controlled pore glass or poly(styrenedivinyl)benzene. The epitope-tagged HGF receptor antagonist can then be eluted from die affinity column using techniques known in the art. In another embodiment of die invention, die HGF receptor antagonist may be fused to a salvage receptor binding epitope in order to increase its serum half-life. This may be achieved, for example, by incoφoration of a salvage receptor binding epitope into a HGF receptor antagonist antibody fragment (e.g., by mutation of the appropriate region in the antibody fragment or by incoφorating the epitope into a peptide tag diat is tiien fused to die antibody fragment at eitiier the end or in die middle, e.g., by DNA or peptide synthesis). A systematic mediod for preparing such a chimera having an increased in vivo half-life comprises several steps. The first involves identifying die sequence and conformation of a salvage receptor binding epitope of an Fc region of an IgG molecule. Once this epitope is identified, the sequence of the HGF receptor antagonist of interest is modified to include die sequence and conformation of the identified binding epitope. After die sequence is mutated, the chimera is tested to see if it has a longer in vivo half-life than that of the original antagonist. If die chimera does not have a longer half-life upon testing, its sequence is further altered to include die sequence and conformation of die identified binding epitope. The salvage receptor binding epitope being incoφorated into the HGF receptor antagonist of interest is any suitable such epitope as defined above, and its nature will depend for example, on the type of antagonist being modified. The transfer is made such diat die HGF receptor antagonist of interest still possesses antagonistic activity. The salvage receptor binding epitope generally constitutes a region wherein any one or more amino acid residues from one or two loops of a Fc domain and is preferably transferred to an analogous position in an HGF receptor antagonist antibody fragment. Preferably, three or more residues from one or two loops of d e Fc domain are transferred, and more preferably, die epitope is taken from die CH2 domain of the Fc region of an IgG and transferred to die CHI, CH3, or V j region, or more than one such region, of the antagonist antibody. Alternatively, the epitope is taken from die CH2 domain of the Fc region and transferred to the C L region or the V-^ region, or both, of the antagonist antibody fragment. In anotiier embodiment die chimeric molecule comprises a HGF receptor antagonist fused to an immunoglobulin constant domain or anotiier heterologous polypeptide such as albumin. This includes chimeras in monomeric, homo- or heteromultimeric form, and particularly heterodimeric form. In general, the chimeric molecules can be constructed in a fashion similar to chimeric antibodies in which a variable domain from an antibody of one species is substituted for the variable domain of another species. See, for example, EP 0 125 023; EP 173,494; Munro, Nature.112:597 (13 December 1984); Neuberger et al., Nature.112:604-608 (13 December 1984); Sharon et al., Nature.102:364-367 (24 May 1984); Morrison et al., Proc. Nat'l. Acad. Sci. USA. £1:6851-6855 (1984); Morrison et al., Spience. 229:1202-1207 (1985); Boulianne et al., Nature.112:643-646 (13 December 1984); Capon et al., Nature. U2:525-531 (1989); Traunecker et al., Nature. U2:68-70 (1989). Preferably, die Ig is a human immunoglobulin when the chimera is intended for in vivo tiierapy for humans. DNA encoding immunoglobulin light or heavy chain constant regions is known or readily available from cDNA libraries or can be synthesized. See for example, Adams et al., Biochemistry.12:2711-2719 (1980); Gough et al., Biochemistry.12:2702-2710 (1980); Dolby et al., Proc. Natl. Acad. Sci.. USA.22:6027-6031 (1980); Rice et al., Proc. Natl. Acad. Sci.. 79:7862-7865 (1982); Falkner et al., Nature.228:286-288 ( 1982); and Morrison et al., Ann. Rev. Immunol.. 2:239-256 ( 1984). Further details of how to prepare such fusions are found in publications concerning the preparation of immunoadhesins. Immunoadhesins in general, and CD4-Ig fusion molecules specifically, are disclosed in WO 89/02922, published 6 April 1989. Molecules comprising die extracellular portion of CD4, the receptor for human immunodeficiency virus (HIV), linked to IgG heavy chain constant region are known in the art and have been found to have a markedly longer half-life and lower clearance than the soluble extracellular portion of CD4 [Capon et al., supra: Byrn et al., Nature.144:667 (1990)]. In another embodiment die chimera comprises a HGF receptor antagonist fused to albumin. Such chimeras may be constructed by inserting the entire coding region of albumin into a plasmid expression vector. The DNA encoding die antagonist can be inserted at the 5' end of the albumin sequence, along with an insert encoding a linker consisting of four glycine residues [Lu et al., FEBS Letters. 156:56-59 (1994)]. The HGF receptor antagonist-albumin chimera can then be expressed in desired mammalian cells or yeast, for instance. C. Methods of Treatment and Diagnosis In another embodiment of die invention, methods for treating cancer are provided. In the methods, HGF receptor antagonist is administered to a mammal diagnosed as having cancer. While die term "cancer" as used herein is not limited to any one specific form of die disease, it is believed diat die methods will be particularly effective for cancers which are found to be accompanied by increased levels of HGF, or overexpression or activation of HGF receptor in die mammal. In a preferred method of die invention, the cancer is breast cancer. It is of course contemplated that the methods of die invention can be employed in combination with still other therapeutic techniques such as surgery. The antagonist is preferably administered to die mammal in a pharmaceutically-acceptable carrier. Suitable carriers and tiieir formulations are described in Remington's Pharmaceutical Sciences. 16th ed., 1980, Mack Publishing Co., edited by Oslo et al. Typically, an appropriate amount of a pharmaceutically- acceptable salt is used in die formulation to render die formulation isotonic. Examples of die pharmaceutically- acceptable carrier include saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antagonist, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to tiiose persons skilled in die art diat certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of antagonist being administered. The antagonist can be administered to the mammal by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular), or by other metiiods such as infusion diat ensure its delivery to die bloodstream in an effective form. The antagonist may also be administered by intratumoral, peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. Local or intravenous injection is preferred. Effective dosages and schedules for administering the antagonist may be determined empirically, and making such determinations is within die skill in die art. Those skilled in die art will understand diat the dosage of antagonist diat must be administered will vary depending on, for example, the mammal which will receive the antagonist the route of administration, the particular type of antagonist used and other drugs being administered to die mammal. Guidance in selecting appropriate doses for antibody antagonists is found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies. Ferrone et al., eds., Noges Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy. Haber et al., eds., Raven Press, New York (1977) pp. 365-389. A typical daily dosage of the antagonist used alone might range from about 1 μg/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above. The antagonist may also be administered to die mammal in combination widi effective amounts of one or more other therapeutic agents or in conjunction with radiation treatment. Therapeutic agents contemplated include chemotiierapeutics as well as immunoadjuvants and cytokines. Chemotherapies contemplated by die invention include chemical substances or drugs which are known in the art and are commercially available, such as Doxorubicin, 5-FIuorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Metiiotrexate, Cisplatin, Melphalan, Vinblastine and Carboplatin. The antagonist may be administered sequentially or concurrently widi die one or more other therapeutic agents. The amounts of antagonist and dierapeutic agent depend, for example, on what type of drugs are used, die cancer being treated, and die scheduling and routes of administration but would generally be less than if each were used individually. Following administration of antagonist to die mammal, die mammal's cancer and physiological condition can be monitored in various ways well known to the skilled practitioner. For instance, tumor mass may be observed physically or 6y standard x-ray imaging techniques. The antagonists of die invention also have utility in non-therapeutic applications. For instance,, metiiods for employing die antagonists in vitro in diagnostic assays are provided. For instance, the antagonists may be employed in diagnostic assays to detect overexpression of HGF receptor in specific cells and tissues. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in eitiier heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of Techniques. CRC Press, Inc. (1987) pp. 147-158]. The antagonists used in die diagnostic assays can be labeled widi a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as H, C, P, 35 S, or I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta- galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antagonist to the detectable moiety may be employed, including tiiose methods described by Hunter et al., Nature.124:495 ( 1962); David et al., Biochemistry. 11:1014-1021 (1974); Pain et al., J. Immunol. Meth.. 40:219-230 (1981); and Nygren, J. Histochem. and Cvtochem..12:407 (1982). Additionally, die HGF receptor antagonist antibodies can be used to immunopurify HGF receptors). D. Articles of Manufacture and Kits In a further embodiment of die invention, there are provided articles of manufacture and kits containing materials useful for treating cancer or detecting or purifying HGF receptor. The article of manufacture comprises a container widi a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition having an active agent which is effective for treating cancer or for detecting or purifying HGF receptor. The active agent in the composition is a HGF receptor antagonist and preferably, comprises Fab fragments of monoclonal antibodies specific for c-Met. The label on the container indicates diat die composition is used for treating cancer or detecting or purifying HGF receptor, and may also indicate directions for either in vivo or in vitro use, such as those described above. The kit of the invention comprises the container described above and a second container comprising a buffer. It may further include otiier materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting die scope of die invention. All reference citations herein are incoφorated by reference. EXAMPLES All restriction enzymes referred to in the examples were purchased from New England Biolabs and used according to manufacturer's instructions. AU other commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in die following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Rockville, Maryland. EXAMPLE 1 Preparation of anti-c-Met Antibodies Balb/c mice (obtained from Charles River Laboratories) were immunized by injecting 2.5 μg/50 μ\ c-Met-IgG fusion protein (diluted in MPL-TDM adjuvant purchased from Ribi Immunochemical Research Inc., Hamilton, MT) five times into each hind foot pad. Injections were administered on Day 0 and Days 56, 63, 66 and 73. The c-Met-IgG fusion protein (including the extracellular domain of c-Met fused to a human IgGl heavy chain) was constructed essentially as described by Mark et al., J. Biol. Chem.. 267:26166- 26171 (1992) and produced in Chinese hamster ovary (CHO) cells. The c-Met-IgG was subsequently purified in a single step using affinity chromatography on immobilized Protein A (Bioprocessing, Inc., Princeton, NJ), using an elution scheme modified from Chamow et al., J. Immunol..151:4268-4280 (1994). Culture supernatant was loaded onto a Protein A column equilibrated in 20 mM Tris, pH 7.4, 0.15 M NaCl. The column was washed, first with equilibration buffer, tiien widi equilibration buffer containing 0.5 M tetramethylammonium chloride, to remove non-specifically bound protein. c-Met-IgG was eluted widi 20 mM Tris, pH 7.4, 3.5 M MgC^. This c-Met-IgG eluate was concentrated and exchanged into 20 mM Tris, pH 7.4, 0.15 M NaCl by gel filtration on Sephadex G25 to a final concentration of about 2-4 mg ml. On Day 77, popliteal lymph nodes were removed from the mice and a single cell suspension was prepared in DMEM media (obtained from Biowhitakker Coφ.) supplemented with 1% penicillin- streptomycin. The lymph node cells were tiien fused widi murine myeloma cells P3X63AgU.l (ATCC CRL 1597) using 35% polyediylene glycol and cultured in 96-well culture plates. Hybridomas resulting from the fusion were selected in HAT medium. Ten days after die fusion, hybridoma culture supernatants were screened in an ELISA to test for the presence of monoclonal antibodies binding to the c-Met-IgG fusion protein. In die ELISA, 96-well microtiter plates (Nunc) were coated by adding 50 μl of 2 μg/ml goat anti-human IgG Fc (purchased from Cappel Laboratories) to each well and incubating at 4° C overnight. The plates were then washed tiiree times with distilled water. The wells in the microtiter plates were blocked with 200 μl of 2% bovine serum albumin and incubated at room temperature for 1 hour. The plates were men washed again three times widi distilled water. After die washing step, 100 μl of 0.4 μg/ml c-Met-IgG fusion protein (as described above) was added to each well. The plates were incubated for 1 hour at room temperature on a shaker apparatus, followed by washing three times with distilled water. Then, 100 μl of die hybridoma supernatants was added to designated wells. 100 μl of P3X63AgU.1 myeloma cell conditioned medium was added to other designated wells as controls. The plates were incubated at room temperature for 1 hour on a shaker apparatus and tiien washed tiiree times with distilled water. Next 50 μl HRP-conjugated goat anti-mouse IgG Fc (purchased from Cappel Laboratories), diluted 1:1000 in assay buffer (0.5% bovine serum albumin, 0.05% Tween-20, 0.01% Thimersol in PBS), was added to each well and die plates incubated for 1 hour at room temperature on a shaker apparatus. The plates were washed three times widi distilled water, followed by addition of 50 μl of substrate (5 mg OPD, 12.5 ml PBS, 5 μl H2O2) to each well and incubation at room temperature for 10 minutes. The reaction was stopped by adding 50 μl of 2 N H2SO4 to each well, and absorbance at 490 ran was read in an automated microtiter plate reader. Of 912 hybridoma supernatants screened in die ELISA, 24 supernatants tested positive (calculated as approximately 2 times above background). The supernatants testing positive in die ELISA were further analyzed by FACS analysis using A549 cells (human epidermoid cell line expressing c-Met; ATCC CCL 185) or BaF3 transfected cells expressing c-Met (see Example 6 below) and fluorescein-conjugated mouse anti- IgG. The FACS analysis showed 19/24 supernatants were positive for anti-c-Met antibodies. EXAMPLE 2 Preparation of anti-c-Met Antibody 5D5.1 1.6 Balb/c mice were immunized as described in Example 1 except that the c-Met-IgG fusion protein injections were administered on Day 0 and Days 7, 14, 21, 28, 211, 273 and 279. On Day 282, lymph nodes were removed and a fusion was conducted as described in Example 1. Hybridoma supernatants were tested according to die ELISA described in Example 1. One of the positive anti-c-Met monoclonal antibodies was called 5D5.11.6 ("5D5"). Further antibody analysis showed that the 5D5 monoclonal antibody is an IgGl isotype antibody comprising a kappa light chain. Ascites was produced in Balb/c mice and die monoclonal antibodies were then purified using a protein G affinity column. The protein concentration was determined by the absorbance at 280 nm using an extinction coefficient of 1.4. EXAMPLE 3 Inhibition Assay of anti-c-Met Antibody 1A3.3.13 to Block HGF Binding An inhibition assay was conducted to examine the ability of the antibodies (described in Example 1) to block binding of HGF to c-Met-IgG fusion protein. Prior to conducting die inhibition assay, the 24 hybridoma supernatants determined positive in the ELISA in Example 1 were purified on Protein A-Sepharose columns to yield antibody preparations of about 1 μg/ml. For the assay, 96-well microtiter plates were coated by adding 100 μl of 2 μg/ml goat anti- human Fc (purchased from Jackson Immunochemical, West Grove, PA) in 0.05 M sodium bicarbonate, pH 9.6, to each well and incubating overnight at 4° C. The plates were then washed with a washing buffer (0.05% Tween-20, 0.01% Thimersol in PBS). Nonspecific binding in die wells was blocked by adding 150 μl blocking buffer (0.5% BSA, 0.01% Thimersol in PBS, pH 7.4) to each well and incubating at room temperature for 2 hours with rapid agitation on an orbital shaker. Next continuing at room temperature and agitation on the orbital shaker, the blocking buffer was removed from die wells, and die plates were washed widi washing buffer. Next 100 μl of 10 ng/ml c-Met- IgG fusion protein in PBS, 0.5% BSA, 0.05% Tween-20, and 0.01% Thimersol (described in Example 1) was added to die wells. The plates were incubated for 2 hours and tiien washed 3 times with washing buffer. Recombinant human HGF (rhuHGF) was produced in CHO cells using a procedure modified from Naka et al., J. Biol. Chem..262:201 14-20119 (1992). rhuHGF-transfected cells were grown in a 400 L bioreactor in medium containing 2% fetal bovine serum for 8 days. Culture supernatant containing rhuHGF was concentrated and clarified, tiien conditioned by die addition of solid NaCl to 0.3 M. rhuHGF was then purified in a single step using cation exchange chromatography. Conditioned, concentrated culture supernatant was loaded onto a column of S-Sepharose Fast Flow equilibrated in 20 mM Tris, pH 7.5, 0.3 M NaCl. After washing out unbound protein, rhuHGF was eluted in a linear gradient from 20 mM Tris, pH 7.5, 0.3 M NaCl to 20 mM Tris, pH 7.5, 1.2 M NaCl. rhuHGF-containing fractions were pooled based on SDS-PAGE analysis. The S Sepharose Fast Flow pool was concentrated and exchanged into 20 mM Tris, pH 7.5, 0.5 M NaCl by gel filtration on Sephadex G25 to a final concentration of about 3-5 mg/ml. A rhuHGF stock solution was then prepared by diluting the rhuHGF in assay buffer (0.5% bovine serum albumin, 0.05% Tween-20, 0.01% Thimersol in PBS) to a concentration of 10 μg/ml. A stock solution of control gpl20 antibody (Genentech. Inc.) was also prepared by diluting die antibody in assay buffer to a concentration of 10 μg/ml. Then, 50 μl of either rhuHGF, gpl20 antibody or one of the 24 monoclonal antibodies was added to designated wells to yield a final concentration of 1000, 100, 10, or 1 ng/ml well. Immediately, 50 μl of 200 ng/ml biotinylated rhuHGF (rhuHGF biotinylated using Biotin-X-NHS obtained from Research Organics, Inc., Cleveland, OH) was also added to each well. After 2 hours incubation, the wells were washed 3 times with washing buffer. 100 μl HRP-streptavidin (1:2000 dilution in assay buffer) (purchased from Zy ed Laboratories), was added to die wells and die plates were incubated for 30 minutes. The plates were washed again 3 times widi washing buffer. 50 μl of substrate (5 mg OPD, 12.5 ml PBS, 5 μl H2O2) was added to the wells and color was allowed to develop for 20 minutes. The reaction was stopped by adding 100 μl 4.5 N sulfuric acid to each well. Absorbance at 492 nm was quantitated in an automated microtiter plate reader. One of the monoclonal antibodies, referred to as 1 A3.3.13, significantly blocked binding of HGF (Figure 2). Further antibody analysis showed diat the 1 A3.3.13 monoclonal antibody is an IgG 1 isotype antibody comprising a kappa light chain. EXAMPLE 4 Mitogenic Assay of Antibodies 3D6, 6G1 and 1 A3.3.13 on Human Mammary Epithelial Cell Line Several different antibodies produced in die fusion described in Example 1, referred to as 3D6, 6G1, and 1 A3.3.13, and purified as described in Example 3, were tested and compared for their ability to induce DNA syndiesis in a human mammary epithelial cell bioassay. Human mammary epithelial cells (obtained from Clonetics Coφ., No. CC-2551 ) were passaged in Mammary Epithelial Cell Basal Medium (Clonetics Coφ., No. CC-3151). Prior to conducting the bioassay, die cells were trypsinized, washed, and resuspended in assay medium (Basal Medium supplemented with 1 mg/ml BSA, penicillin, streptomycin and L-glutamine) to a concentration of 1 x 10 cells/ml. Next, 100 μl of the cells were added to die wells of 96-well culture plates. rhuHGF (described in Example 3) was diluted in assay medium at concentrations of 20 ng/ml and 200 ng/ml. The 3D6, 6G1, 1A3.3.13, and control gp 120 antibodies were diluted in assay medium at concentrations of 200 ng/ml and 2 μg/ml. 100 μl of the rhuHGF and antibody preparations was then added to designated wells. The plates were incubated at 37° C in 5% CO2 for 16 hours. Next 1 μCi H-tiiymidine (Amersham) was added to each well, and die plates were incubated for 24 hours at 37° and 5% CO2. The human mammary epithelial cells were harvested and the amount of radioactivity incoφorated into the DNA was then quantitated in a microplate scintillation counter. The results showed that at a concentration of 10 ng/ml, the 3D6, 6G1 and 1 A3.3.12 antibodies have some HGF agonistic effect. (See Figure 3) EXAMPLE 5 Mitogenic Assay of Antibodies 05-237 and 05-238 on Mink Lung Cell Line Anti-c-Met antibodies 05-237 and 05-238 (purchased from Upstate Biotechnology Inc.. Lake Placid, NY; see also, Prat et al., Mol. Cell. Biol.. supra. Prat et al., Int. J. Cancer, supra) and antibody 3D6 (described in Example 4) were tested and compared for their ability to induce DNA synthesis in a mink lung bioassay. Mink lung cells (Mv 1 Lu, ATCC CC164) were passaged in DME/F12 (50:50) supplemented widi 10% fetal bovine serum, penicillin, streptomycin and L-glutamine. Prior to conducting the bioassay, the mink lung cells were trypsinized, washed, and resuspended in assay medium (DME/F12 medium supplemented with 1 mg/ml BSA, penicillin, streptomycin and L-glutamine) to a concentration of 1 x 10 5 cells/ml. The bioassay was then conducted as described in Example 4. The results showed diat antibodies 05-237 and 05-238 have HGF agonistic effect. (See Figure 4) EXAMPLE 6 Antagonistic Activity of Monoclonal Antibody 1 A3.3.13 Fab Antagonistic activity of 1 A3.3.13 monoclonal antibody Fab fragments was determined using athymidine incoφoration assay. Monoclonal antibody 1A3.3.13 (described in Example 3) was digested with papain to obtain the Fab fragments. The papain digestion was performed by initially dialyzing the antibody against a 20 mM phosphate/ 10 mM EDTA, pH 7.0, buffer overnight. The antibody was tiien concentrated to approximately 10 mg/ml. Next, 0.5 ml immobilized papain (crosslinked 6% beaded agarose, obtained from Pierce Chemicals) was added to a 16 x 100 mm tube. The papain beads were washed 2 times with 4 ml of digestion buffer (42 mg cysteine-HCl in 12 ml phosphate buffer, pH 10). Each wash was removed using a separator. About 0.5 to 1 ml of the 1A3.3.13 antibody was added to the papain beads and then incubated in a heated shaker batii (37° C, 200 rpm) overnight. 1.5 ml of binding buffer (Immunopure IgG Binding Buffer obtained from Pierce Chemicals) was added to die tube, and the supernatant was separated from the beads with a separator. The supernatant was then passed over a Protein A column equilibrated with the binding buffer. Additional binding buffer was passed over die column and the eluate containing the Fab fragments was collected in 1 ml fractions. The fractions were analyzed by absorbance at 280 nm and the Fab containing fractions dialyzed against PBS overnight. Absorbance at 280 nm was read again to determine the concentration of Fab (about 1.53). The fractions were also run on a 7.5% SDS gel to determine the purity of the Fab in the fraction. The 1 A3.3.13 Fab fragments were further tested in an inhibition assay (as described in Example 3). The Fab fragments did inhibit HGF binding but showed a weaker inhibitory effect as compared to intact 1 A3.3.13 antibody (data not shown). An expression plasmid was prepared by inserting a full-length cDNA for human c-Met (described as pOK met cDNA in Rodrigues et al., supra) into a pRK5.tk.neo vector [de Sauvage et al., Nature. 162:533-538 (1994); Gorman, DNA Cloning: A New Approach. 2:143-190 (IRL Washington 1985)]. The resulting plasmid was linearized and transfected into the IL-3 dependent cell line, BaF3 [Palacios et al., Cell. 41:727-734 (1985)] by electroporation (800 microfarad, 250 V, BRL electroporator). Selection of transfectants was performed by culturing die cells for 2-3 weeks in the presence of 2 mg/ml G418. One of the selected transfectant cell lines, referred to as BaF3-hmet.8, was confirmed by Western blotting to express c-Met. BaF3- hmet.8 also tested positive for response to HGF in a proliferation assay measuring incoφoration of 3 H- diymidine. Neither the parental BaF3 cells nor any cells derived by transfection with the pRK5.tk.neo vector alone ("BaF3-neo") were found to express c-Met or respond to HGF in tiie proliferation assay. The BaF3-hmet.8 cells were passaged in RPMI medium supplemented widi 10% fetal bovine serum, 5% WEHI-conditioned medium (as a source of IL-3) and 2 mM glutamine. Prior to conducting die assay, die cells were washed twice widi assay medium (RPMI medium supplemented widi 10% fetal bovine serum) and resuspended in assay medium to a concentration of 5 x 10 4 cells/ml. Next 100 μl of the cells was added to each well in die 96-well culture plates. Various concentrations (0.2 μg/ml, 2 μg/ml, 20 μg/ml) of control gp 120 Fab fragments (gp 120 monoclonal antibody digested widi papain as described above) and the 1 A3.3.13 Fab fragments were prepared in assay medium and 100 μl was added to designated wells. The plates were incubated at 37° C in 5% C0 2 for 15 hours. One μCi H-thymidine was added to each well of die culture plates. The cells were harvested 7 hours later and die amount of radioactivity incoφorated into the DNA was quantitated (CPM) in a microplate scintillation counter. The results are shown in Figure 5. At a concentration of 10 μg/ml, the 1A3.3.13 Fab fragments significantly blocked BaF3-hmet.8 cell proliferation in the presence of HGF. EXAMPLE 7 Preparation of 5D5 Antibody Fab The 5D5 monoclonal antibody (as described in Example 2) was dialyzed and digested with papain essentially as described in Example 6 except diat after dialysis, die antibody was concentrated to 7 mg/ml using a Centricon 30 filter. After dialyzing die 5D5 Fab fragments against PBS overnight die preparation of 5D5 Fab fragments was further purified by gel filtration (Superose M 12, Pharmacia) to remove residual F(ab') 2 . EXAMPLE 8 Assay of 5D5 Antibody and 5D5 Fab Binding to c-Met The binding specificity of die 5D5 antibody (described in Example 2) was examined by incubating BaF3-hmet cells or BaF3-neo cells (each described in Example 6) with saturating concentrations of 5D5 antibody ora control IgG, followed by fluorescein-coπjugated mouse anti-IgG. 10 μg/ml 5D5 antibody was incubated widi 50 μl of 1 x 10 5 BaF3-hmet cells or BaF3-neo cells for 30 minutes at 4° C in cell sorting buffer (PBS and 1% fetal calf serum). The cells were washed twice with cell sorting buffer and spun at 1500 φm for 5 minutes. The cells were then incubated with 100 μl goat (Fab')2 anti-mouse IgG Fc (Cappel) at a 1 :1000 dilution for 30 minutes at 4° C. The cells were again washed twice with cell sorting buffer and spun at 1500 φm for 5 minutes. The cells were then transferred to microtiter tubes with 250 μl of cell sorting buffer and analyzed by flow cytometry widi a Becton Dickinson FACScan. As shown in Figures 6A and 6B, die 5D5 antibody binds to die BaF3-hmet cells but not to the BaF3-neo cells, indicating diat 5D5 antibody binds c-Met. An inhibition assay was also conducted, essentially as described in Example 3, to examine die ability of 5D5 antibody (Example 2) and 5D5 Fab (described in Example 7) to block binding of HGF to c-Met- IgG fusion protein. rhuHGF, 5D5 antibody, 5D5 Fab and control gp 120 Fab were tested at concentrations ranging from 0 to 10 μg/ml, as shown in Figure 7. Each data point in die graph of Figure 7 is the mean of triplicates. The data illustrated in Figure 7 shows d at botii the 5D5 antibody and 5D5 Fab blocked binding of HGF to c-Met-IgG. EXAMPLE 9 Antagonistic Activity of 5D5 Fab A. BaF3-hmet Cell Assay Antagonistic activity of 5D5 Fab fragments was examined using a tivymidine incoφoration assay, as described in Example 6. Various concentrations (0, 0.01, 0.1, 1, 10 μg/ l) of control gp 120 Fab and 5D5 Fab (Example 7) were prepared in die assay medium and added to designated wells, either alone or in the presence of 10 ng ml rhuHGF. The results are shown in Figures 8 A and 8B. Data are the mean ± SEM of 4 replicates in a representative experiment. As shown in Figures 8A and 8B, the 5D5 Fab acts as an antagonist at concentrations as low as 1 μg/ml, significantly blocking BaF3-hmet cell proliferation in the presence of HGF. B. Human Mammary Tumor Cell Assay Antagonistic activity of 5D5 Fab fragments was examined in a mitogenic assay to measure induction of DNA syndiesis in a human breast carcinoma cell line. MDA-MB-435 human breast carcinoma cells (ATCC HTB 129) (which express c-Met) were cultured in DMEM, 5% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin sulfate and 2 mM glutamine. Prior to conducting the assay, the cells were washed and resuspended in assay medium (DMEM, 0.1% BSA, 2mM glutamine). The cells were then plated in a 96 well plate at 5,000 cells/well and incubated at 37° C with varying concentrations of rhuHGF (0, 0.1, 1, 10, 100, 1000 ng/ml) in the absence or presence of 10 μg/ml 5D5 Fab (Example 7) overnight. Next, 1 μCi H-thymidine was added to each well and the plates were incubated for 24 hours at 37° C. The cells were then harvested and die amount of radioactivity incoφorated into die DNA was quantitated in a microplate scintillation counter. The results are shown in Figure 9. Data are die mean + SEM of 6 replicates in a representative experiment. As shown in Figure 9, die mitogenic response of the carcinoma cells to the HGF was completely blocked by 5D5 Fab. EXAMPLE 10 Effect of 5D5 Fab on Tyrosine Phosphorylation of c-Met The ability of 5D5 Fab to stimulate the c-Met receptor or induce c-Met activation was examined in an in vitro assay measuring c-Met tyrosine phosphorylation. Phosphorylation of c-Met was measured in a sandwich ELISA, based on the methods of Sadick et al. in which solubilized c-Met is captured onto a plate coated with rabbit anti-c-Met polyclonal IgG and detected with anti-P-Tyr [Sadick et al., Anal. Biochem..215:207-214 (1996)]. Microtiter plates were coated overnight at 4° C with 5 μg/ml rabbit anti-c-Met polyclonal IgG, then non-specific binding was blocked as described in Example 3. While the microtiter plates were coated, A549 cells (described in Example 1) were plated into 100 mm dishes. The next day the cells were washed twice widi assay medium (MEM supplemented widi 1% BSA) and tiien challenged for 10 minutes with NK1 (1 μg/ml) [NK1 prepared as described in Lokker et al., J. Biol. Chem..26£:17145-17150 (1993)] or 5D5 Fab alone (10 μg/ml) (Example 7) or widi rhuHGF (10 ng/ml) (Example 3). The cells were washed twice with PBS, and then lysed in 1 ml lysis buffer (PBS, 0.2% Triton X-100, 10 μg/ml aprotonin, 5 mM NaF, 2 mM sodium orthovanadate, and 0.2 mM PMSF) for 30 minutes on an orbital shaker at room temperature. The lysate was centrifuged for 10 minutes and 100 μl supernatant was transferred in duplicate to die blocked microtiter plates. After incubation for 2 hours at 23° C, tyrosine phosphorylation was detected by incubation for 2 hours at 23° C with biotin-anti-P-Tyr (Upstate Biotech, Lake Placid, NY), followed by HRP-streptavidin. Next TMB peroxidase substrate (KPL, Gaithersburg, MD) was added. The reaction was stopped with phosphoric acid and OD was measured at 450 nm in an automatic plate reader. Total c-Met was measured in parallel wells incubated as above except that detection was with biotinylated rabbit anti-c-Met polyclonal IgG (NIHS biotin, Pierce Chemical). As shown in Figures 10A and 10B, lysates were analyzed for relative amounts of tyrosine phosphorylated c-Met (Fig. 10A) and total c-Met (Fig. 10B). Results shown in Figures 10A and 10B are the mean + SEM of 4 replicates from a representative experiment. NK1 did stimulate tyrosine phosphorylation of c-Met (indicating agonistic activity), but did not significantly inhibit the response of A549 cells to the HGF. In contrast, 5D5 Fab had no stimulatory effect on tyrosine phosphorylation and blocked HGF responses. EXAMPLE 11 Effect of Heparin on Antagonistic Activity of 5D5 Fab The effect of heparin on die antagonistic activity of 5D5 Fab was examined using a thymidine incoφoration assay, as described in Examples 6 and 9 except diat BaF3-hmet cells were incubated widi N 1 (described in Example 10; 0, 0,01, 0.1, 1 μg/ml), 5D5 Fab (described in Example 7; 0, 0.01, 0.1, 1, 10 μg/ml) or 5D5 Fab and 10 ng/ml HGF. Each incubation was done in the absence or presence of heparin (1 μg/ml) (Sigma). The results, shown in Figures 11 A-l IC, are the mean ± SEM of 4 replicates from a representative experiment. As shown in Figure 11 A, NK1 can be converted to an agonistic molecule by the presence of exogenous heparin. In contrast heparin did not confer agonist activity on the 5D5 Fab (Figure 1 IB). Although the response to HGF was enhanced by heparin, the 5D5 Fab remained an antagonist and completely blocked HGF activity (Figure 11 C). EXAMPLE 12 Effect of 5D5 Fab on HGF-Induced Cell Migration An assay was conducted to examine the ability of 5D5 Fab to inhibit HGF-induced cell migration. A549 cells (described in Example 1) were added to the upper wells of a 48-well modified Boyden chamber (NEURO PROBE INC., Cabin John, MD) containing rhuHGF ( 10 ng/ml) and/or 5D5 Fab (Example 7; 10 μg/ml) in die lower wells. A barrier of polyvinylpyrrolidone-free polycarbonate filter with 8 micron pore size was employed. After incubation for 6 hours at 37° C, die cells on e upper surface of the membrane were scraped off, and die membrane was stained widi DifQuik τ (Baxter Scientific Products). A549 cells that had migrated onto die lower side of die membrane were counted in 20 randomly selected fields for each well. The data shown in Table 1 below are the mean + SD of 4 wells. TABLE 1 Inhibition of HGF-induced migration by 5D5 Fab Number of Cells Migrated per High Powered Field Experiment 1 Experiment 2 Control O ± O 9 ± 8 HGF 224 ± 30 35 ± 10 5D5 Fab 2 ± 2 7 ± 4 HGF + 5D5 Fab 37 ± 22 6 ± 4 The results show that 5D5 Fab blocked migration responses to HGF. EXAMPLE 13 Sequencing. Cloning and Expression of 5D5 Fab An aliquot of 5D5 Fab (Example 7) was resolved on a 4-20% gradient SDS gel and electroblotted onto a PVDF (Immobilon-PSQ) membrane (Millipore, Marlborough, MA) for 1 hour at 250 mA constant current in a BioRad Trans-Blot transfer cell [Matsudaira, J. Biol. Chem..262:10035-10038 (1987)]. The membrane was tiien stained with 0.1% Coomassie Blue R-250 in 50% methanol for 30 seconds and destained for 2-3 minutes with 10% acetic acid in 50% methanol. After destaining, die membrane was thoroughly washed with water and allowed to dry before sequencing on a model 473A automated protein sequencer, using a Blott TM cartridge (Applied Biosystems). Peaks were integrated widi Justice Innovation software using Nelson Analytical 760 interfaces and sequence inteφretation was performed on a DEC alpha [Henzel et al., J. Chromatography. 404:41-52 (1996)]. Obtaining sequence of the 5D5 heavy chain required deblocking, which was performed as follows. The Fab fragment was reduced widi 7 mM DTT at 45° C for 1 hour and alkylated with 180 mM isopropylacetamide at 25° C for 20 minutes [Krutzsch et al., Anal. Biochem.. 222:109-116 (1993)]. The alkylated Fab fragment was then exchanged 3X in a Microcon- 10 with 0.1 M sodium phosphate containing 10 mM DTT (in digestion buffer) and digested widi 1 mU of pyroglumate aminopeptidase (Takara Biochemicals, Berkeley, CA) at 45° C for 3 hours in 20 μl digestion buffer. The deblocked Fab was then transferred to the PVDF membrane and sequenced as described above. N-terminal sequence data were used to design PCR primers specific for the 5' ends of the variable regions of the light and heavy chains, while 3' primers were designed to anneal to the concensus framework 4 of each chain [Kabat et al., Sequences of Proteins of Immunological Interest Public Health Service, National Institutes of Healtii, Bethesda, MD, (1991)]. The primers were also designed to add restriction enzyme sites for cloning. Total RNA, extracted from 10° cells of hybridoma 5D5 with a Stratagen RNA isolation kit, was used as substrate for RT-PCR. Reverse transcription was performed under standard conditions [Kawasaki et al., PCR Protocols:A Guide to Methods and Applications. Innis et al., eds., Academic Press, San Diego, pp. 21-27 (1990)] using die framework 4 specific primers and Superscript II RNase H-Reverse Transcriptase (Gibco- BRL, Gaithersburg, MD). PCR amplification employed Taq polymerase (Perkin Elmer-Cetus, Foster City, CA), as described in Kawasaki et al., supra, except diat 2% DMSO was included in the reaction mixture. Amplified DNA fragments were digested with restriction enzymes Sfil and RsrII (light chain) or Mlul and Apal (heavy chain), gel purified, and cloned into a derivative of expression plasmid pAK19 [Carter et al., Bio/Technologv. 12:163-167 (1992)]. This vector, pXCA730, was modified by site-directed mutagenesis [Kunkel et al., Proc. Natl. Acad. Sci.. £2:488 (1985)] to contain unique restriction sites between the STII signal sequences and the variable domains, and at die junction of the variable and constant domains of each chain. The light and heavy chain variable domain cDNAs were inserted upstream and in frame to human CK and CHI domains. The C- terminal cysteine of the heavy chain in pAK19, which could form a disulfide bridge to give F(ab')2 molecules, was removed to permit expression of only the Fab form of die antibody. Recombinant 5D5 Fab was expressed in E. coli K12 strain 33B6 [Rodrigues et al., Cancer Res.. 55:63-70 (1995)], as described by Carter et al., supra. Figure 12 shows a schematic representation of plasmid p5D5 containing die discistronic operon for expression of die chimer 5D5 Fab. Expression was under the control of die E. coli alkaline phosphatase promoter, which is inducible by phosphate starvation. Each antibody chain was preceded by die E. coli heat-stable enterotoxin II signal sequence to direct sequence to the periplasmic space of E. coli. The murine variable domains from antibody 5D5 (V-^ and VJJ) were precisely fused on their 3' side to human K j C^ and C-^ j constant domains, respectively. The cell pellet from a 10-L fermentation was harvested by continuous feed centrifugation. frozen and stored at -70° C. A portion of die pellet was suspended in extraction buffer (120 mM MES, pH 6.0, and 5 mM EDTA, 5 ml/gram of paste). The suspension was mixed thoroughly using an ultraturrax (Janke and Kunkel) for approximately 15 minutes at 4° C. Intact cells were then disrupted using 2 passes through a cell homogenizer (Microfluidizer, by Microfluidics Coφ., Newton, MA) fitted widi a cooling coil. The suspension was en adjusted to 0.1% (v/v) polyetiiyleneimine using a 5% (v/v) stock which had been adjusted to pH 6.0. Intact cells and PEI-flocculated debris were separated from die soluble fraction by centrifugation at 25,400x g for 30 minutes. The supernatant was adjusted to a conductivity less tiian 4 mS by addition of purified water and loaded onto a column (1 x 10 cm) of Bakerbond ABX, 40 micron particle size (J.T. Baker, Phillipsburg, N.J.). The column had been equilibrated in 50 mM MES, 5 mM EDTA, pH 6.0. All steps were done at a linear flow rate of 100 cm/hour. After loading, die column was washed widi equilibration buffer until the absorbance of the column effluent was equivalent to baseline. Elution was performed using a 16-column volume, linear gradient from 0 to 100 mM ammonium sulfate in equilibration buffer. Column fractions were analyzed by SDS- polyacrylamide gel electrophoresis and fractions which contained die Fab were pooled. The conductivity of the pool from the ABX column was lowered to less tiian 4 mS and loaded onto a column (1 x 10 cm) of SP- Sepharose High Performance resin (Pharmacia Biotech, Piscataway, N.J.) that had been equilibrated in 25 mM MOPS buffer, pH 6.9. All steps were performed at a linear flow rate of 100 cm/hour. Following the load, the column was washed widi one column volume of equilibration buffer. The 5D5 Fab was then eluted from the column using a 16-column volume, linear gradient from 0 to 200 mM sodium acetate in equilibration buffer. Column fractions were analyzed by SDS-polyacrylamide gel electrophoresis and fractions which contained the Fab were pooled. The light chain of die 5D5 Fab included amino acid residues 1 to 220, as shown in Figure 1 A (SEQ ID NO:l), and die heavy chain included amino acid residues 1 to 230 (wherein amino acid residue 1 comprised a glutamic acid residue), as shown in Figure IB (SEQ ID NO:2). Molecular weight analysis of the 5D5 Fab showed diat it had a molecular weight of approximately 45 kDa. Although not fully understood, it is believed diat amino acid residue 1 of native 5D5 Fab heavy chain may be a glutamine residue. EXAMPLE 14 Assay of Recombinant 5D5 Fab Binding to c-Met An inhibition assay was conducted, essentially as described in Examples 3 and 8, to examine the ability of recombinant 5D5 Fab (Example 13) to block binding of HGF to c-Met-IgG fusion protein. rhuHGF, recombinant 5D5 Fab, or a recombinant control Fab (anti-VEGF Fab, Genentech, Inc.) were tested at concentrations ranging from 0.001 - 10 μg/ml, as shown in Figure 13. The data, shown in Figure 13, is die mean + SD of duplicate wells. The graph in Figure 13 illustrates that the recombinant 5D5 Fab inhibited HGF binding to c-Met while the control did not. EXAMPLE 15 Effect of Heparin on Antagonistic Activity of Recombinant 5D5 Fab The effect of heparin on antagonistic activity of recombinant 5D5 Fab (Example 13) was examined using a tirymidine incoφoration assay as described in Examples 6, 9 and 11. BaF3-hmet cells were incubated with 0 - 10,000 ng/ml recombinant 5D5 Fab (Example 13) or recombinant control Fab alone (anti- VEGF Fab; described in Example 14), with 1 μg/ml heparin (Sigma), widi 10 ng/ml rhuHGF, or with 10 ng/ml rhuHGF plus 1 μg/ml heparin. The results are shown in Figures 14A-14D, and die data are the mean + SEM of 4 replicates in a representative experiment. The results show that the recombinant 5D5 Fab remained an antagonist in the presence and absence of heparin. Deposit of Materials The following cultures have been deposited widi die American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC): Hvbridoma ATCC No. Deposit Date 1A3.3.13 HB-11894 May 23, 1995 5D5.11.6 HB-11895 May 23, 1995 This deposit was made under the provisions of die Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Puφose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of viable cultures for 30 years from the date of deposit. The organisms will be made available by ATCC under die terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by die U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and die Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638). The assignee of the present application has agreed diat if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited strains are not to be construed as a license to practice the invention in contravention of die rights granted under die autiiority of any government in accordance with its patent laws. The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cultures deposited, since the deposited embodiments are intended as an illustration of an aspect of the invention and any cultures that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission diat die written description herein contained is inadequate to enable die practice of any aspect of the invention, including die best mode diereof, nor is it to be construed as limiting die scope of the claims to the specific illustration that it represents. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Genentech, Inc. Schwall, Ralph H. Tabor, Kelly Helen (ii) TITLE OF INVENTION: Hepatocyte Growth Factor Receptor Antagonists and Uses Thereof (iii) NUMBER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Genentech, Inc. (B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA (F) ZIP: 94080 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: WinPatin (Genentech) (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/460368 (B) FILING DATE: 02-JUN-1995 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Marschang, Diane L. (B) REGISTRATION NUMBER: 35,600 (C) REFERENCE/DOCKET NUMBER: P0938P1PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 415/225-5416 (B) TELEFAX: 415/952-9881 (C) TELEX: 910/371-7168 (2) INFORMATION FOR SEQ ID Nθ:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 220 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:l: Asp lie Met Met Ser Gin Ser Pro Ser Ser Leu Thr Val Ser Val 1 5 10 15 Gly Glu Lys Val Thr Val Ser Cys Lys Ser Ser Gin Ser Leu Leu 20 25 30 Tyr Thr Ser Ser Gin Lys Asn Tyr Leu Ala Trp Tyr Gin Gin Lys 35 40 45 Pro Gly Gin Ser Pro Lys Leu Leu lie Tyr Trp Ala Ser Thr Arg 50 55 60 Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr 65 70 75 Asp Phe Thr Leu Thr lie Thr Ser Val Lys Ala Asp Asp Leu Ala 80 85 90 Val Tyr Tyr Cys Gin Gin Tyr Tyr Ala Tyr Pro Trp Thr Phe Gly 95 100 105 Gly Gly Thr Lys Leu Glu lie Lys Arg Thr Val Ala Ala Pro Ser 110 115 120 Val Phe lie Phe Pro Pro Ser Asp Glu Gin Leu Lys Ser Gly Thr 125 130 135 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 140 145 150 Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin Ser Gly Asn Ser 155 160 165 Gin Glu Ser Val Thr Glu Gin Asp Ser Lys Asp Ser Thr Tyr Ser 170 175 180 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 185 190 195 Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro 200 205 210 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 215 220 (2) INFORMATION FOR SEQ ID Nθ:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 230 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:2: Glx Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Arg Pro Gly 1 5 10 15 Ala Ser Val Lys Met Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr 20 25 30 Ser Tyr Trp Leu His Trp Val Lys Gin Arg Pro Gly Pro Gly Leu 35 40 45 Glu Trp lie Gly Met lie Asp Pro Ser Asn Ser Asp Thr Arg Phe 50 55 60 Asn Pro Asn Phe Lys Asp Lys Ala Thr Leu Asn Val Asp Arg Ser 65 70 75 Ser Asn Thr Ala Tyr Met Leu Leu Ser Ser Leu Thr Ser Ala Asp 80 85 90 Ser Ala Val Tyr Tyr Cys Ala Thr Tyr Gly Ser Tyr Val Ser Pro 95 100 105 Leu Asp Tyr Trp Gly Gin Gly Thr Ser Val Thr Val Ser Ser Ala 110 115 120 Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 125 130 135 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 140 145 150 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 155 160 165 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly 170 175 180 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 185 190 195 Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn 200 205 210 Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 215 220 225 His Thr Ala Ala Pro 230 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 660 base pairs (B) TYPE: Nucleic Acid (C) STRANDEDNESS: Single (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GACATTATGA TGTCCCAGTC TCCATCCTCC CTAACTGTGT CAGTTGGAGA 50 GAAGGTTACT GTGAGCTGCA AGTCCAGTCA GTCCCTTTTA TATACTAGCA 100 GTCAGAAGAA CTACTTGGCC TGGTACCAGC AGAAACCAGG TCAGTCTCCT 150 AAACTGCTGA TTTACTGGGC ATCCACTAGG GAATCTGGGG TCCCTGATCG 200 CTTCACAGGC AGTGGATCTG GGACAGATTT CACTCTCACC ATCACCAGTG 250 TGAAGGCTGA CGACCTGGCA GTTTATTACT GTCAGCAATA TTATGCCTAT 300 CCGTGGACGT TCGGTGGAGG CACAAAGTTG GAGATCAAAC GGACCGTGGC 350 TGCACCATCT GTCTTCATCT TCCCGCCATC TGATGAGCAG TTGAAATCTG 400 GAACTGCCTC TGTTGTGTGC CTGCTGAATA ACTTCTATCC CAGAGAGGCC 450 AAAGTACAGT GGAAGGTGGA TAACGCCCTC CAATCGGGTA ACTCCCAGGA 500 GAGTGTCACA GAGCAGGACA GCAAGGACAG CACCTACAGC CTCAGCAGCA 550 CCCTGACGCT GAGCAAAGCA GACTACGAGA AACACAAAGT CTACGCCTGC 600 GAAGTCACCC ATCAGGGCCT GAGCTCGCCC GTCACAAAGA GCTTCAACAG 650 GGGAGAGTGT 660 (2) INFORMATION FOR SEQ ID Nθ:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 690 base pairs (B) TYPE: Nucleic Acid (C) STRANDEDNESS: Single (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:4: SAGGTTCAGC TGCAGCAGTC TGGGCCTGAA CTGGTGAGGC CTGGGGCTTC 50 AGTGAAAATG TCCTGCAGGG CTTCGGGCTA TACCTTCACC AGCTACTGGT 100 TGCACTGGGT TAAACAGAGG CCTGGACCAG GCCTTGAGTG GATTGGCATG 150 ATTGATCCTT CCAATAGTGA CACTAGGTTT AATCCGAACT TCAAGGACAA 200 GGCCACATTG AATGTAGACA GATCTTCCAA CACAGCCTAC ATGCTGCTCA 250 GCAGCCTGAC ATCTGCTGAC TCTGCAGTCT ATTACTGTGC CACATATGGT 300 AGCTACGTTT CCCCTCTGGA CTACTGGGGT CAAGGAACCT CAGTCACCGT 350 CTCTTCCGCC TCCACCAAGG GCCCATCGGT CTTCCCCCTG GCACCCTCCT 400 CCAAGAGCAC CTCTGGGGGC ACAGCGGCCC TGGGCTGCCT GGTCAAGGAC 450 TACTTCCCCG AACCGGTGAC GGTGTCGTGG AACTCAGGCG CCCTGACCAG 500 CGGCGTGCAC ACCTTCCCGG CTGTCCTACA GTCCTCAGGA CTCTACTCCC 550 TCAGCAGCGT GGTGACCGTG CCCTCCAGCA GCTTGGGCAC CCAGACCTAC 600 ATCTGCAACG TGAATCACAA GCCCAGCAAC ACCAAGGTCG ACAAGAAAGT 650 TGAGCCCAAA TCTTGTGACA AAACTCACAC AGCTGCGCCG 690

Claims: WHAT IS CLAIMED IS: 1. A hepatocyte growth factor (HGF) receptor antagonist which specifically binds to a HGF receptor. 2. The antagonist of Claim 1 which is an antibody. 3. The antibody of Claim 2 which is a monoclonal antibody. 4. The antibody of Claim 2 wherein the antibody binds to the c-Met receptor. 5. The antibody of Claim 4 wherein the antibody inhibits binding of human HGF to the c-Met receptor. 6. The antibody of Claim 2 which comprises a Fab fragment. 7. The antibody of Claim 2 comprising a chimeric antibody. 8. The antibody of Claim 2 having the biological characteristics of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB- 1 1894. 9. The antibody of Claim 2 wherein the antibody binds to substantially the same epitope as the epitope to which die monoclonal antibody produced by die hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11894 binds. 10. The antibody of Claim 2 having the biological characteristics of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB- 11895. 11. The antibody of Claim 2 wherein the antibody binds to substantially the same epitope as the epitope to which die monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11895 binds. 12. An isolated HGF receptor antagonist which specifically binds to a HGF receptor and comprises amino acid residues 1-220 of Figure 1 A and amino acid residues 1-230 of Figure IB. 13. An isolated nucleic acid encoding die HGF receptor antagonist of Claim 12. 14. An isolated nucleic acid encoding the HGF receptor antagonist of Claim 1. 15. The nucleic acid of Claim 14 wherein said antagonist is an antibody. 16. A vector comprising the nucleic acid of Claim 12. 17. A host cell comprising the vector of Claim 16. 18. A method of producing HGF receptor antagonist comprising culturing the host cell of Claim 17 and recovering the HGF receptor antagonist from the host cell culture. 19. A hybridoma cell line which produces die antibody of Claim 3. 20. The hybridoma of Claim 19 comprising ATCC HB- 11894. 21. The hybridoma of Claim 19 comprising ATCC HB- 11895. 22. A chimeric molecule comprising the HGF receptor antagonist of Claim 1 or Claim 12 fused to a heterologous polypeptide sequence. 23. The chimeric molecule of Claim 22 wherein said heterologous polypeptide is a tag polypeptide sequence. 24. The chimeric molecule of Claim 22 wherein said heterologous polypeptide sequence is an immunoglobulin sequence. 25. The chimeric molecule of Claim 22 wherein said heterologous polypeptide sequence is an albumin sequence. 26. A pharmaceutical composition comprising the HGF receptor antagonist of Claim 1 of Claim 12 and a pharmaceutically-acceptable carrier. 27. The pharmaceutical composition of Claim 26 wherein said antagonist is an antibody. 28. A mediod of treating cancer in a mammal, comprising administering an effective amount of HGF receptor antagonist to a mammal diagnosed as having cancer. 29. The method of Claim 28 wherein said antagonist is an antibody. 30. The mediod of Claim 28 wherein said cancer is breast cancer. 31. The mediod of Claim 28 wherein said cancer is pancreatic cancer. 32. The method of Claim 28 wherein said cancer is colon cancer. 33. The method of Claim 28 wherein said cancer is lung cancer. 34. An article of manufacture, comprising: a container; a label on said container; and a composition contained within said container; wherein the composition includes an active agent effective for treating cancer, the label on said container indicates diat the composition can be used for treating cancer, and the active agent in said composition comprises HGF receptor antagonist. 35. The article of manufacture of Claim 34 wherein said antagonist is an antibody. 36. The article of manufacture of Claim 34 further comprisinginstructions for administering the HGF receptor antagonist to a mammal. 37. A kit, comprising: a first container, a label on said container, and a composition contained within said container; wherein die composition includes an active agent effective for treating cancer, the label on said container indicates diat the composition can be used for treating cancer, and die active agent in said composition comprises HGF receptor antagonist; a second container comprising a pharmaceutically-acceptable buffer; and instructions for using theHGF receptor antagonist to treat cancer. 38. An article of manufacture, comprising: a container; a label on said container; and a composition contained within said container; wherein die composition includes an active agent effective for detecting or purifying HGF receptor, the label on said container indicates diat die composition can be used for detecting or purifying HGF receptor, and die active agent in said composition comprises HGF receptor antagonist. 39. The article of manufacture of Claim 38 wherein said antagonist is an antibody. 40. A kit comprising: a first container, a label on said container, and a composition contained within said container; wherein the composition includes an active agent effective for detecting or purifying HGF receptor, the label on said container indicates diat die composition can be used for detecting or purifying HGF receptor, and die active agent in said composition comprises HGF receptor antagonist; a second container comprising a pharmaceutically-acceptable buffer; and instructions for using the HGF receptor antagonist to detect or purify HGF receptor.

Inventors: SCHWALL RALPH H, TABOR KELLY HELEN, SCHWALL, RALPH, H., TABOR, KELLY, HELEN
Applicants: GENENTECH INC, SCHWALL RALPH H, TABOR KELLY HELEN, GENENTECH, INC., SCHWALL, RALPH, H., TABOR, KELLY, HELEN
Application year: 1996
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K45, A61P35, C07K16, C10G65, C12N5, C12N15, C12P21, C12R1, G01N33